Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

(Mark One)


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 0-24260

AMEDISYS, INC.

(Exact Name of Registrant as Specified in its Charter)



Delaware						11-3131700
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

AMED

The NASDAQ Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

☒

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date, is as follows: Common stock, $0.001 par value, 32,633,347 shares outstanding as of October 20, 2023.

TABLE OF CONTENTS



SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS		1
;;;
PART I.	FINANCIAL INFORMATION
ITEM 1.	FINANCIAL STATEMENTS:
	CONDENSED CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2023 (UNAUDITED) AND DECEMBER 31, 2022	2
	CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2023 AND 2022 (UNAUDITED)	3
	CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2023 AND 2022 (UNAUDITED)	4
	CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2023 AND 2022 (UNAUDITED)	5
	NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	7
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	27
ITEM 3	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	48
ITEM 4.	CONTROLS AND PROCEDURES	48

PART II. OTHER INFORMATION
ITEM 1.	LEGAL PROCEEDINGS	50
ITEM 1A.	RISK FACTORS	50
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	52
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	52
ITEM 4.	MINE SAFETY DISCLOSURES	52
ITEM 5.	OTHER INFORMATION	53
ITEM 6.	EXHIBITS	54
SIGNATURES		55

SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS

When included in this Quarterly Report on Form 10-Q, or in other documents that we file with the Securities and Exchange Commission (“SEC”) or in statements made by or on behalf of the Company, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “will,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to, the following: disruption from the proposed merger with UnitedHealth Group with patient, payor, provider, referral source, supplier or management and employee relationships; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement with UnitedHealth Group or the inability to complete the proposed transaction on the anticipated terms and timetable; the risk that necessary regulatory approvals for the proposed merger with UnitedHealth Group are delayed, are not obtained or are obtained subject to conditions that are not anticipated; the failure of the conditions to the proposed merger to be satisfied; the costs related to the proposed transaction; the diversion of management time on merger-related issues; the risk that termination fees may be payable by the Company in the event that the merger agreement is terminated under certain circumstances; reputational risk related to the proposed merger; the risk of litigation or regulatory action related to the proposed merger; changes in Medicare and other medical payment levels; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients and payment methodologies; staffing shortages driven by the competitive labor market; our ability to attract and retain qualified personnel; competition in the healthcare industry; our ability to maintain or establish new patient referral sources; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; the impact of the novel coronavirus pandemic ("COVID-19") on our business, financial condition and results of operations; changes in estimates and judgments associated with critical accounting policies; our ability to consistently provide high-quality care; our ability to keep our patients and employees safe; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural or man-made disasters, climate change or acts of terrorism, widespread protests or civil unrest; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; our ability to integrate, manage and keep our information systems secure; the impact of inflation; and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking, and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law. For a discussion of some of the factors discussed above as well as additional factors, see our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 16, 2023, particularly, Part I, Item 1A - Risk Factors therein, and Part II, Item 1A. Risk Factors of this Quarterly Report on Form 10-Q. Additional risk factors may also be described in reports that we file from time to time with the SEC.

Available Information

Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website (under the link “SEC filings”), free of charge, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as reasonably practicable after we electronically file or furnish such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation, Quality of Care, Compliance and Ethics and Nominating and Corporate Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link “Governance”). Reference to our website does not constitute incorporation by reference of the information contained on the website and should not be considered part of this document. Our electronically filed reports can also be obtained on the SEC’s internet site at http://www.sec.gov.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

AMEDISYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except share data)


	September 30, 2023 (Unaudited)		December 31, 2022
ASSETS
Current assets:
Cash and cash equivalents	$	78,112	$	40,540
Restricted cash	15,904		13,593
Patient accounts receivable	319,580		296,785
Prepaid expenses	20,534		11,628
Other current assets	33,097		26,415
Total current assets	467,227		388,961
Property and equipment, net of accumulated depreciation of $93,909 and $101,364	39,631		16,026
Operating lease right of use assets	87,834		102,856
Goodwill	1,244,679		1,287,399
Intangible assets, net of accumulated amortization of $12,838 and $14,604	103,634		101,167
Other assets	84,412		79,836
Total assets	$	2,027,417	$	1,976,245
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	34,555	$	43,735
Payroll and employee benefits	126,989		125,387
Accrued expenses	139,100		137,390
Termination fee paid by UnitedHealth Group	106,000		—
Current portion of long-term obligations	35,364		15,496
Current portion of operating lease liabilities	26,111		33,521
Total current liabilities	468,119		355,529
Long-term obligations, less current portion	366,853		419,420
Operating lease liabilities, less current portion	61,878		69,504
Deferred income tax liabilities	35,398		20,411
Other long-term obligations	1,651		4,808
Total liabilities	933,899		869,672
Commitments and Contingencies—Note 6
Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding	—		—
Common stock, $0.001 par value, 60,000,000 shares authorized; 38,065,853 and 37,891,186 shares issued; 32,633,599 and 32,511,465 shares outstanding	38		38
Additional paid-in capital	776,880		755,063
Treasury stock, at cost, 5,432,254 and 5,379,721 shares of common stock	(465,613)		(461,200)

Retained earnings	728,603		757,672
Total Amedisys, Inc. stockholders’ equity	1,039,908		1,051,573
Noncontrolling interests	53,610		55,000
Total equity	1,093,518		1,106,573
Total liabilities and equity	$	2,027,417	$	1,976,245

The accompanying notes are an integral part of these condensed consolidated financial statements.

AMEDISYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except per share data)

(Unaudited)


	For the Three-Month Periods Ended September 30,				For the Nine-Month Periods Ended September 30,
	2023		2022		2023		2022
Net service revenue	$	556,237	$	557,988	$	1,665,594	$	1,661,135
Operating expenses:
Cost of service, inclusive of depreciation	311,628		322,227		924,093		943,258
General and administrative expenses:
Salaries and benefits	129,083		125,550		380,926		376,788
Non-cash compensation	6,612		3,495		18,968		15,990
Merger-related expenses	4,980		—		25,151		—
Depreciation and amortization	4,436		5,477		13,604		19,705
Investment impairment	—		3,009		—		3,009
Other	57,287		59,299		180,467		167,851
Total operating expenses	514,026		519,057		1,543,209		1,526,601
Operating income	42,211		38,931		122,385		134,534
Other income (expense):
Interest income	1,304		59		2,452		108
Interest expense	(8,021)		(4,963)		(23,040)		(16,447)
Equity in earnings (loss) from equity method investments	1,252		302		9,366		(442)
Merger termination fee	—		—		(106,000)		—
Miscellaneous, net	1,201		491		5,262		1,155
Total other expense, net	(4,264)		(4,111)		(111,960)		(15,626)
Income before income taxes	37,947		34,820		10,425		118,908
Income tax expense	(12,331)		(9,417)		(40,381)		(32,755)
Net income (loss)	25,616		25,403		(29,956)		86,153
Net loss attributable to noncontrolling interests	344		239		887		739
Net income (loss) attributable to Amedisys, Inc.	$	25,960	$	25,642	$	(29,069)	$	86,892
Basic earnings per common share:
Net income (loss) attributable to Amedisys, Inc. common stockholders	$	0.80	$	0.79	$	(0.89)	$	2.67
Weighted average shares outstanding	32,624		32,482		32,587		32,519
Diluted earnings per common share:
Net income (loss) attributable to Amedisys, Inc. common stockholders	$	0.79	$	0.79	$	(0.89)	$	2.66
Weighted average shares outstanding	32,831		32,616		32,587		32,680

The accompanying notes are an integral part of these condensed consolidated financial statements.

AMEDISYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Amounts in thousands, except common stock shares)

(Unaudited)


	For the Three-Months Ended September 30, 2023
	Total		Common Stock			Additional Paid-in Capital		Treasury Stock		Retained Earnings		Noncontrolling Interests
			Shares	Amount
Balance, June 30, 2023	$	1,060,757	38,030,397	$	38	$	768,789	$	(464,688)	$	702,643	$	53,975
Issuance of stock – employee stock purchase plan	848		10,915	—		848		—		—		—
Issuance/(cancellation) of non-vested stock	—		24,117	—		—		—		—		—
Exercise of stock options	25		424	—		25		—		—		—
Non-cash compensation	7,243		—	—		7,243		—		—		—
Surrendered shares	(925)		—	—		—		(925)		—		—
Purchase of noncontrolling interest	—		—	—		(25)		—		—		25
Noncontrolling interest contributions	856		—	—		—		—		—		856
Noncontrolling interest distributions	(902)		—	—		—		—		—		(902)
Net income (loss)	25,616		—	—		—		—		25,960		(344)
Balance, September 30, 2023	$	1,093,518	38,065,853	$	38	$	776,880	$	(465,613)	$	728,603	$	53,610

	For the Three-Months Ended September 30, 2022
	Total		Common Stock			Additional Paid-in Capital		Treasury Stock		Retained Earnings		Noncontrolling Interests
			Shares	Amount
Balance, June 30, 2022	$	1,038,995	37,780,242	$	38	$	743,276	$	(457,981)	$	700,313	$	53,349
Issuance of stock – employee stock purchase plan	966		10,814	—		966		—		—		—
Issuance/(cancellation) of non-vested stock	—		57,420	—		—		—		—		—
Exercise of stock options	306		3,583	—		306		—		—		—
Non-cash compensation	3,495		—	—		3,495		—		—		—
Surrendered shares	(3,187)		—	—		—		(3,187)		—		—
Noncontrolling interest contributions	1,148		—	—		—		—		—		1,148
Noncontrolling interest distributions	(450)		—	—		—		—		—		(450)
Sale of noncontrolling interest	2,934		—	—		2,871		—		—		63
Net income (loss)	25,403		—	—		—		—		25,642		(239)
Balance, September 30, 2022	$	1,069,610	37,852,059	$	38	$	750,914	$	(461,168)	$	725,955	$	53,871

	For the Nine-Months Ended September 30, 2023
	Total		Common Stock			Additional Paid-in Capital		Treasury Stock		Retained Earnings		Noncontrolling Interests
			Shares	Amount
Balance, December 31, 2022	$	1,106,573	37,891,186	$	38	$	755,063	$	(461,200)	$	757,672	$	55,000
Issuance of stock – employee stock purchase plan	2,602		37,408	—		2,602		—		—		—
Issuance/(cancellation) of non-vested stock	—		135,563	—		—		—		—		—
Exercise of stock options	100		1,696	—		100		—		—		—
Non-cash compensation	19,624		—	—		19,624		—		—		—
Surrendered shares	(4,413)		—	—		—		(4,413)		—		—
Purchase of noncontrolling interest	(630)		—	—		(509)		—		—		(121)
Noncontrolling interest contributions	1,232		—	—		—		—		—		1,232
Noncontrolling interest distributions	(1,614)		—	—		—		—		—		(1,614)
Net loss	(29,956)		—	—		—		—		(29,069)		(887)
Balance, September 30, 2023	$	1,093,518	38,065,853	$	38	$	776,880	$	(465,613)	$	728,603	$	53,610

	For the Nine-Months Ended September 30, 2022
	Total		Common Stock			Additional Paid-in Capital		Treasury Stock		Retained Earnings		Noncontrolling Interests
			Shares	Amount
Balance, December 31, 2021	$	976,323	37,674,868	$	38	$	728,118	$	(435,868)	$	639,063	$	44,972
Issuance of stock – employee stock purchase plan	2,857		24,159	—		2,857		—		—		—
Issuance/(cancellation) of non-vested stock	—		141,726	—		—		—		—		—
Exercise of stock options	1,078		11,306	—		1,078		—		—		—
Non-cash compensation	15,990		—	—		15,990		—		—		—
Surrendered shares	(7,949)		—	—		—		(7,949)		—		—
Shares repurchased	(17,351)		—	—		—		(17,351)		—		—
Noncontrolling interest contributions	11,000		—	—		—		—		—		11,000
Noncontrolling interest distributions	(1,425)		—	—		—		—		—		(1,425)
Sale of noncontrolling interest	2,934		—	—		2,871		—		—		63
Net income (loss)	86,153		—	—		—		—		86,892		(739)
Balance, September 30, 2022	$	1,069,610	37,852,059	$	38	$	750,914	$	(461,168)	$	725,955	$	53,871

The accompanying notes are an integral part of these condensed consolidated financial statements.

AMEDISYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands)

(Unaudited)


	For the Nine-Month Periods Ended September 30,
	2023		2022
Cash Flows from Operating Activities:
Net (loss) income	$	(29,956)	$	86,153
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization (inclusive of depreciation included in cost of service)	17,956		19,705
Non-cash compensation	19,624		15,990
Amortization and impairment of operating lease right of use assets	25,427		34,782
Loss on disposal of property and equipment	346		507
Loss on personal care divestiture	2,186		—
Merger termination fee	106,000		—
Deferred income taxes	15,417		19,031
Equity in (earnings) loss from equity method investments	(9,366)		442
Amortization of deferred debt issuance costs	743		743
Return on equity method investments	4,309		3,798
Investment impairment	—		3,009
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable	(32,934)		(18,266)
Other current assets	(15,434)		(19,929)
Operating lease right of use assets	(2,803)		(2,323)
Other assets	273		283
Accounts payable	(8,839)		5,886
Accrued expenses	10,340		(26,790)
Other long-term obligations	(3,156)		243
Operating lease liabilities	(23,256)		(30,864)
Net cash provided by operating activities	76,877		92,400
Cash Flows from Investing Activities:
Proceeds from the sale of deferred compensation plan assets	25		89
Proceeds from the sale of property and equipment	100		66
Purchases of property and equipment	(3,728)		(4,338)
Investments in technology assets	(6,881)		(848)
Investment in equity method investee	—		(637)
Purchase of cost method investment	—		(15,000)
Return of investment	150		—
Proceeds from personal care divestiture	47,787		—
Acquisitions of businesses, net of cash acquired	(350)		(71,952)
Net cash provided by (used in) investing activities	37,103		(92,620)
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options	100		1,078
Proceeds from issuance of stock under employee stock purchase plan	2,602		2,857
Shares withheld to pay taxes on non-cash compensation	(4,413)		(7,949)
Noncontrolling interest contributions	1,232		2,100
Noncontrolling interest distributions	(1,614)		(1,425)
Proceeds from sale of noncontrolling interest	—		3,941
Proceeds from borrowings under revolving line of credit	23,000		484,000
Repayments of borrowings under revolving line of credit	(23,000)		(465,500)
Principal payments of long-term obligations	(67,113)		(10,126)
Purchase of company stock	—		(17,351)
Payment of accrued contingent consideration	(4,091)		(5,714)
Purchase of noncontrolling interest	(800)		—
Net cash used in financing activities	(74,097)		(14,089)
Net increase (decrease) in cash, cash equivalents and restricted cash	39,883		(14,309)
Cash, cash equivalents and restricted cash at beginning of period	54,133		45,769
Cash, cash equivalents and restricted cash at end of period	$	94,016	$	31,460


	For the Nine-Month Periods Ended September 30,
	2023		2022
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	$	19,787	$	9,153
Cash paid for Infinity ZPIC interest	$	—	$	11,544
Cash paid for income taxes, net of refunds received	$	24,318	$	23,582
Cash paid for operating lease liabilities	$	26,059	$	33,187
Cash paid for finance lease liabilities	$	8,462	$	1,074
Supplemental Disclosures of Non-Cash Activity:
Right of use assets obtained in exchange for operating lease liabilities	$	25,261	$	36,980
Right of use assets obtained in exchange for finance lease liabilities	$	34,964	$	1,846
Reductions to right of use assets resulting from reductions to operating lease liabilities	$	15,135	$	3,387
Reductions to right of use assets resulting from reductions to finance lease liabilities	$	1,209	$	564
Accrued contingent consideration	$	—	$	19,195
Noncontrolling interest contribution	$	—	$	8,900

The accompanying notes are an integral part of these condensed consolidated financial statements.

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS

Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as “Amedisys,” “we,” “us,” or “our”), is a multi-state provider of home health, hospice and high acuity care services with approximately 73% of our consolidated net service revenue derived from Medicare for the three and nine-month periods ended September 30, 2023, and approximately 74% of our consolidated net service revenue derived from Medicare for the three and nine-month periods ended September 30, 2022. As of September 30, 2023, we owned and operated 346 Medicare-certified home health care centers, 165 Medicare-certified hospice care centers and 10 admitting high acuity care joint ventures in 37 states within the United States and the District of Columbia. We divested our personal care business on March 31, 2023.

Amedisys and UnitedHealth Group Incorporated Merger

On June 26, 2023, Amedisys, UnitedHealth Group Incorporated, a Delaware corporation ("UnitedHealth Group"), and Aurora Holdings Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"), entered into an Agreement and Plan of Merger, pursuant to which Merger Sub will merge with and into Amedisys with Amedisys continuing as the surviving corporation and becoming a wholly owned subsidiary of UnitedHealth Group. See Note 4 - Mergers, Acquisitions and Dispositions for additional information.

Basis of Presentation

In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.

This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission (“SEC”) on February 16, 2023 (the “Form 10-K”), which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations.

Recently Issued Accounting Pronouncements

In August 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-05, Business Combinations (Topic 805): Joint Venture Formations, which requires that a joint venture initially measure all contributions received upon its formation at fair value. The guidance is effective for joint ventures with a formation date on or after January 1, 2025 on a prospective basis.

Use of Estimates

Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Reclassification

Certain reclassifications have been made to prior periods' financial statements in order to conform to the current year presentation. These reclassifications had no effect on our previously reported net income. See Note 7 - Segment Information for additional information regarding these reclassifications.

Principles of Consolidation

These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that we either consolidate, account for under the equity method of accounting or account for under the cost method of accounting. See Note 3 - Investments for additional information.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

We account for service revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers, and as such, we recognize service revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material.

Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals.

Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from audits and payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change.

Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current industry conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs.

Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.

We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation based on our historical collection experience.

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Net service revenue by payor class as a percentage of total net service revenue for each segment is as follows:


	For the Three-Month Periods Ended September 30,				For the Nine-Month Periods Ended September 30,
	2023		2022		2023		2022
Home Health:
Medicare	39	%	40	%	39	%	40	%
Non-Medicare - Episodic-based	7	%	7	%	8	%	8	%
Non-Medicare - Non-episodic based	17	%	13	%	15	%	13	%
Hospice:
Medicare	34	%	34	%	34	%	33	%
Non-Medicare	2	%	2	%	2	%	2	%
Personal Care	—	%	3	%	1	%	3	%
High Acuity Care	1	%	1	%	1	%	1	%
	100	%	100	%	100	%	100	%

Home Health Revenue Recognition

Medicare Revenue

All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each 60-day episode includes two 30-day payment periods.

Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity’s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient, and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.

The Patient-Driven Groupings Model ("PDGM") uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b) a low utilization payment adjustment (“LUPA”) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group; (c) a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.

Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical collection experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.

Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.

The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services and receive treatment under a plan of care established and periodically reviewed by a physician.

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Effective January 1, 2022, the Centers for Medicare and Medicaid Services ("CMS") implemented a new notice of admission ("NOA") process. The NOA process requires a one-time submission for each patient that establishes the home health period of care and covers all contiguous 30-day periods of care until the patient is discharged from home health services. If the NOA is not submitted timely, a payment reduction is applied equal to 1/30 of the 30-day payment rate for each day from the start of care until the date the NOA is submitted.

Non-Medicare Revenue

Payments from non-Medicare payors are either a percentage of Medicare rates, per-visit rates or case rates depending upon the terms and conditions established with such payors. Approximately 30% of our managed care contract volume affords us the opportunity to receive additional payments if we achieve certain quality or process metrics as defined in each contract (e.g. star ratings and acute-care hospitalization rates). We record revenue associated with these metrics at the time the amounts are probable and estimable.

Episodic-based Revenue. We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.

Non-episodic based Revenue. For our per visit contracts, gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. For our case rate contracts, gross revenue is recorded over our historical average length of stay using the established case rate for each admission. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.

Under our case rate contracts, we may receive reimbursement before all services are rendered. Any cash received that exceeds the associated revenue earned is recorded to deferred revenue in accrued expenses within our condensed consolidated balance sheets.

Hospice Revenue Recognition

Hospice Medicare Revenue

Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three and nine-month periods ended September 30, 2023 and 2022. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (“SIA”). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.

The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.

We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical collection experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.

Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded. We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

28th of the following year. As of September 30, 2023, we have recorded $3.5 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October 31, 2017 through September 30, 2023. As of December 31, 2022, we had recorded $4.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October 31, 2016 through September 30, 2023.

Hospice Non-Medicare Revenue

Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.

Personal Care Revenue Recognition

Personal Care Revenue

For the periods prior to our divestiture of our personal care line of business on March 31, 2023, we generated net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that was either contractual or fixed by legislation. Net service revenue was recognized at the time services were rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We received payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors included the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA").

High Acuity Care Revenue Recognition

High Acuity Care Revenue

Our revenues are primarily derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans and (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home.

Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a 30-day (H@H) or 60-day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the 30-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the 60-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians’ orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first five to seven days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenue over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.

Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient’s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, net service revenue is recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.

We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.

Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. The Company maintains cash with commercial banks, which are insured by the Federal Deposit Insurance Corporation (“FDIC”). At various times, the Company has deposits in these financial institutions in excess of the amount insured by the FDIC. The Company has not experienced any losses related to these balances and believes its credit risk to be minimal.

Restricted cash includes cash that is not available for ordinary business use. As of September 30, 2023 and December 31, 2022, we had $15.9 million and $13.6 million, respectively, classified as restricted cash related to funds placed into escrow accounts in connection with the indemnity, closing payment and other provisions within the purchase agreements of our acquisitions and divestitures. See Note 4 - Mergers, Acquisitions and Dispositions for additional information regarding funds placed into escrow.

The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):


	As of September 30, 2023		As of December 31, 2022
Cash and cash equivalents	$	78.1	$	40.5
Restricted cash	15.9		13.6
Cash, cash equivalents and restricted cash	$	94.0	$	54.1

Patient Accounts Receivable

We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. Our non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of September 30, 2023, there is only one single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables (approximately 14%). Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represented 65% and 67% of our patient accounts receivable at September 30, 2023 and December 31, 2022, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor.

We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.

Medicare Home Health

For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare following the end of each 30-day period of care or upon discharge, if earlier, for the services provided to the patient.

Medicare Hospice

For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care

For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient’s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.

Business Combinations

We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, Business Combinations. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and any noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.

Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):


			Fair Value at Reporting Date Using
Financial Instrument	Carrying Value as of September 30, 2023		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-term obligations	$	377.5	$	—	$	373.3	$	—

The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:

•Level 1 – Quoted prices in active markets for identical assets and liabilities.

•Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•Level 3 – Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.

Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Weighted-Average Shares Outstanding

Net income (loss) per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income (loss) attributable to Amedisys, Inc. common stockholders (amounts in thousands):


	For the Three- Month Periods Ended September 30,		For the Nine- Month Periods Ended September 30,
	2023	2022	2023	2022
Weighted average number of shares outstanding - basic	32,624	32,482	32,587	32,519
Effect of dilutive securities:
Stock options	10	38	—	50
Non-vested stock and stock units	197	96	—	111
Weighted average number of shares outstanding - diluted	32,831	32,616	32,587	32,680
Anti-dilutive securities	248	202	652	276

3. INVESTMENTS

We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.

We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $45.5 million and $40.5 million as of September 30, 2023 and December 31, 2022, respectively, and is reflected in other assets within our condensed consolidated balance sheets.

We account for investments in entities in which we have less than 20% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. During the three-month period ended March 31, 2022, we made a $15.0 million investment in a home health benefit manager, which is accounted for under the cost method. The book value of investments that we account for under the cost method of accounting was $20.0 million as of September 30, 2023 and December 31, 2022 and is reflected in other assets within our condensed consolidated balance sheets.

Our high acuity care segment includes interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of September 30, 2023, we are consolidating all but one of our admitting joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. Additionally, from time to time, we may be required to provide joint venture funding. Our high acuity care segment also includes one admitting joint venture with a health system partner that is accounted for under the equity method of accounting.

During the three-month period ended September 30, 2022, we recorded a $3.0 million impairment charge in connection with the wind down of operations of one of our high acuity care joint ventures.

The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs’ assets and liabilities included in our condensed consolidated balance sheets are as follows (amounts in millions):

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)


	As of September 30, 2023		As of December 31, 2022
ASSETS
Current assets:
Cash and cash equivalents	$	8.6	$	15.6
Patient accounts receivable	7.0		6.1
Other current assets	0.1		0.6
Total current assets	15.7		22.3
Property and equipment	0.1		0.1
Operating lease right of use assets	0.1		0.1
Goodwill	8.5		8.5
Intangible assets	0.4		0.4
Other assets	0.1		0.2
Total assets	$	24.9	$	31.6
LIABILITIES
Current liabilities:
Accounts payable	$	0.4	$	0.1
Payroll and employee benefits	0.8		0.5
Accrued expenses	6.9		5.8
Operating lease liabilities	—		0.1
Current portion of long-term obligations	—		0.2
Total liabilities	$	8.1	$	6.7

4. MERGERS, ACQUISITIONS AND DISPOSITIONS

Mergers

On June 26, 2023, Amedisys, UnitedHealth Group Incorporated, a Delaware corporation ("UnitedHealth Group"), and Aurora Holdings Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"), entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which Merger Sub will merge with and into Amedisys with Amedisys continuing as the surviving corporation and becoming a wholly owned subsidiary of UnitedHealth Group (the “Merger”).

Subject to the terms and conditions set forth in the Merger Agreement, at the effective time of the Merger (the "Effective Time"), by virtue of the Merger: (i) each share of Amedisys common stock (“Amedisys Common Stock”) held in treasury by Amedisys or owned by UnitedHealth Group or Merger Sub or any of their respective subsidiaries, in each case, immediately prior to the Effective Time will be cancelled (collectively, “cancelled shares”) without consideration; and (ii) each share of Amedisys Common Stock, other than any cancelled shares, issued and outstanding immediately prior to the Effective Time will be converted into the right to receive $101 per share in cash, without interest, less any applicable withholding taxes.

The Merger is subject to a number of conditions to closing as specified in the Merger Agreement. These closing conditions include, among others, (i) approval by Amedisys stockholders at the Amedisys Stockholders Meeting (as defined in the Merger Agreement) of the proposal to adopt the Merger Agreement, which approval was obtained on September 8, 2023; (ii) the expiration or termination of the applicable waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; (iii) the receipt of the required state regulatory approvals; (iv) the absence of any law or order that has the effect of enjoining or otherwise prohibiting the completion of the Merger; and (v) the expiration or early termination of the waiting period (and any extension thereof) applicable to the consummation of the transactions contemplated by the Merger Agreement under all applicable antitrust laws without the imposition by any governmental entity of any term, condition, obligation, requirement, limitation, prohibition, remedy, sanction or other action that has resulted in or would reasonably be expected to result in a Burdensome Condition (as defined in the Merger Agreement).

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

As previously disclosed in Amedisys’ Current Report on Form 8-K filed with the SEC on May 3, 2023 and its Quarterly Report on Form 10-Q filed with the SEC on May 4, 2023, Amedisys entered into an Agreement and Plan of Merger on May 3, 2023 (the “OPCH Merger Agreement”) with Option Care Health, Inc., a Delaware corporation (“OPCH”), and Uintah Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of OPCH (“OPCH Merger Sub”). On June 26, 2023, Amedisys, OPCH and OPCH Merger Sub entered into the Termination Agreement (the “Termination Agreement”), pursuant to which the parties thereto agreed to terminate the OPCH Merger Agreement and grant mutual releases by the parties of all claims against the other parties based upon, arising from, in connection with or relating to the OPCH Merger Agreement. Pursuant to the terms of the Termination Agreement, each of the termination of the OPCH Merger Agreement and the mutual releases provided for in the Termination Agreement would become effective upon receipt by OPCH of a $106,000,000 termination fee payable by, or on behalf of, Amedisys within 24 hours of the execution of the Termination Agreement (i.e., before the market open on June 27, 2023). On June 26, 2023, following the execution of the Termination Agreement, UnitedHealth Group, on behalf of Amedisys, delivered funds to OPCH in an amount equal to $106,000,000, representing the termination fee payable to OPCH under the OPCH Merger Agreement and the Termination Agreement, satisfying the condition precedent to the effectiveness of the termination of the OPCH Merger Agreement and the releases contained in the Termination Agreement. If the Merger Agreement is terminated under certain specified circumstances, Amedisys may be required to reimburse UnitedHealth Group for the $106,000,000 termination fee that UnitedHealth Group, on Amedisys’ behalf, paid to OPCH in addition to the $125,000,000 termination fee payable by Amedisys to UnitedHealth Group upon termination of the Merger Agreement. The $106,000,000 termination fee was recorded to other income (expense) within our condensed consolidated statement of operations with a corresponding liability to termination fee paid by UnitedHealth Group within our condensed consolidated balance sheet during the three-month period ended June 30, 2023.

Acquisitions

We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice and high acuity care services. The purchase price paid for acquisitions is negotiated through arm’s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.

2023 Acquisitions

On January 20, 2023, we acquired the regulatory assets of a home health provider in West Virginia for a purchase price of $0.4 million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $0.3 million and other intangibles (certificate of need) of $0.1 million in connection with the acquisition.

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

2022 Acquisitions

On April 1, 2022, we acquired 15 home health care centers from Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati ("Evolution"), for an estimated purchase price of $67.8 million. A portion of the purchase price ($51.1 million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($16.7 million) was placed into an escrow account in accordance with the closing payment, indemnity and other provisions within the purchase agreement.

Of the total $16.7 million placed into escrow, $1.0 million was set aside for the closing payment adjustment. The closing payment calculated on the acquisition date included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price was subject to an adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. The closing payment adjustment, which was finalized during the three-month period ended September 30, 2022, reduced the purchase price by $1.3 million from $67.8 million to $66.5 million. The remaining $15.7 million placed into escrow relates to certain outstanding matters existing as of the acquisition date as well as potential losses the Company may incur for which the seller has an obligation to indemnify the Company. This amount will either be paid to third parties as outstanding matters are resolved or to the seller at certain intervals in the future. As of September 30, 2023, $9.6 million of the total $16.7 million has been released from escrow; $7.1 million plus interest remains in escrow and is reflected as restricted cash within our condensed consolidated balance sheet. Corresponding liabilities related to these contingent consideration arrangements are reflected in accrued expenses within our condensed consolidated balance sheet as of September 30, 2023.

$15 million of goodwill recorded for this acquisition will be deductible for income tax purposes over approximately two to five years.

The Company finalized its valuation of the assets acquired and liabilities assumed during the three-month period ended March 31, 2023. As a result of our review, total assets acquired decreased $0.2 million (primarily patient accounts receivable) and total liabilities assumed remained flat; these adjustments resulted in a $0.2 million increase in goodwill during the three-month period ended March 31, 2023. The total consideration of $66.5 million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)


	Amount
ASSETS
Patient accounts receivable	$	7.3
Prepaid expenses	0.2
Other current assets	0.1
Property and equipment	1.9
Operating lease right of use assets	3.2
Intangible assets (licenses)	1.3
Deferred income tax asset	0.1
Other assets	0.1
Total assets acquired	$	14.2
LIABILITIES
Accounts payable	$	(0.8)
Payroll and employee benefits	(2.6)
Accrued expenses	(2.6)
Operating lease liabilities	(2.8)
Current portion of long-term obligations	(0.6)
Total liabilities assumed	(9.4)
Net identifiable assets acquired	$	4.8
Goodwill	61.7
Total consideration	$	66.5

On April 1, 2022, we acquired two home health locations from AssistedCare Home Health, Inc. and RH Homecare Services, LLC, doing business as AssistedCare Home Health and AssistedCare of the Carolinas ("AssistedCare"), respectively, for a purchase price of $24.7 million. A portion of the purchase price ($22.2 million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($2.5 million) was placed into an escrow account in accordance with the indemnity provisions within the purchase agreement and is reflected in restricted cash within our condensed consolidated balance sheet. A corresponding liability related to this contingent consideration arrangement is reflected in accrued expenses within our condensed consolidated balance sheet as of September 30, 2023. The $2.5 million will either be paid to third parties or to the seller at certain intervals in the future. As of September 30, 2023, the entire $2.5 million plus interest remains in escrow.

We recorded goodwill of $24.0 million and other intangibles of $0.7 million in connection with the acquisition. Intangible assets acquired include licenses ($0.5 million), certificates of need ($0.2 million) and acquired names (less than $0.1 million). The acquired names were amortized over a weighted average period of one year. The entire amount of goodwill recorded for this acquisition will be deductible for income tax purposes over approximately 15 years.

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Dispositions

On February 10, 2023, we signed a definitive agreement to sell our personal care business (excluding the Florida operations, which were closed during the three-month period ended March 31, 2023). The divestiture closed on March 31, 2023. We received net proceeds of $47.8 million and recognized a $2.2 million loss during the three-month period ended March 31, 2023, which is reflected in miscellaneous, net within our condensed consolidated statement of operations. The net proceeds of $47.8 million is inclusive of $6.0 million that was placed into an escrow account in accordance with the closing payment and indemnity provisions within the purchase agreement; this amount is recorded as restricted cash within our condensed consolidated balance sheet as of September 30, 2023.

Of the total $6.0 million placed into escrow, $1.0 million was set aside for the closing payment adjustment. The closing payment calculated on the acquisition date included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price was subject to an adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. The closing payment adjustment was finalized during the three-month period ended September 30, 2023 with $0.1 million being paid to Amedisys by the buyer. The $1.0 million in escrow related to the closing payment adjustment was released to Amedisys during the fourth quarter. The remaining $5.0 million placed into escrow relates to potential losses for which the Company may have to indemnify the buyer. As of September 30, 2023, the entire $6.0 million plus interest remained in escrow.

The disposition of our personal care business did not qualify as a discontinued operation because it did not represent a strategic shift that has or will have a major effect on the Company's operations or financial results.

We derecognized goodwill of $43.1 million in connection with the divestiture. The carrying amounts of the assets and liabilities associated with our personal care reporting unit included in our condensed consolidated balance sheet as of December 31, 2022 were as follows (amounts in millions):


	As of December 31, 2022
ASSETS
Current assets:
Patient accounts receivable	$	9.6
Prepaid expenses	0.1
Total current assets	9.7
Property and equipment	0.1
Operating lease right of use assets	2.5
Goodwill	43.1
Total assets	$	55.4
LIABILITIES
Current liabilities:
Accounts payable	$	0.4
Payroll and employee benefits	0.6
Accrued expenses	1.8
Current portion of operating lease liabilities	0.6
Total current liabilities	3.4
Operating lease liabilities, less current portion	1.9
Total liabilities	$	5.3

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

5. LONG-TERM OBLIGATIONS

Long-term debt consists of the following for the periods indicated (amounts in millions):


	September 30, 2023		December 31, 2022
$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Term SOFR plus Applicable Rate (7.2% at September 30, 2023); due July 30, 2026	$	377.5	$	435.9
$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Term SOFR plus Applicable Rate; due July 30, 2026	—		—
Promissory notes	—		0.2
Finance leases	27.5		2.3
Principal amount of long-term obligations	405.0		438.4
Deferred debt issuance costs	(2.8)		(3.5)
	402.2		434.9
Current portion of long-term obligations	(35.3)		(15.5)
Long-term obligations, less current portion	$	366.9	$	419.4

Second Amendment to the Credit Agreement

On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provided for a senior secured credit facility in an initial aggregate principal amount of up to $1.0 billion, which includes a $550.0 million Revolving Credit Facility and a term loan facility with a principal amount of up to $450.0 million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").

Third Amendment to the Credit Agreement

On March 10, 2023, we entered into the Third Amendment to our Credit Agreement (as amended by the Third Amendment, the "Third Amended Credit Agreement"). The Third Amended Credit Agreement (i) formally replaced the use of the London Interbank Offered Rate ("LIBOR") with the Secured Overnight Financing Rate ("SOFR") for interest rate pricing and (ii) allowed for the disposition of our personal care business.

The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Term SOFR plus the Applicable Rate. The “Base Rate” means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Term SOFR plus 1% per annum. The “Term SOFR” means the quoted rate per annum equal to the SOFR for an interest period of one or three months (as selected by us) plus the SOFR adjustment of 0.10%. The “Applicable Rate” is based on the consolidated leverage ratio and is presented in the table below. As of September 30, 2023, the Applicable Rate is 0.75% per annum for Base Rate loans and 1.75% per annum for Term SOFR loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Third Amended Credit Agreement, as presented in the table below.


Pricing Tier	Consolidated Leverage Ratio	Base Rate Loans	Term SOFR Loans and SOFR Daily Floating Rate Loans	Commitment Fee	Letter of Credit Fee
I	> 3.00 to 1.0	1.00%	2.00%	0.30%	1.75%
II	< 3.00 to 1.0 but > 2.00 to 1.0	0.75%	1.75%	0.25%	1.50%
III	< 2.00 to 1.0 but > 0.75 to 1.0	0.50%	1.50%	0.20%	1.25%
IV	< 0.75 to 1.0	0.25%	1.25%	0.15%	1.00%

The final maturity date of the Amended Credit Facility is July 30, 2026. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Amended Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) 0.625% for the period commencing on July 30, 2021 and ending on September 30, 2023, and (ii) 1.250% for the period commencing on October 1, 2023 and ending on July 30, 2026. The remaining balance of the

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Amended Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Amended Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Amended Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5 million or (b) any debt issuance that is not permitted under the Third Amended Credit Agreement.

In accordance with the requirements above, net proceeds received from the divestiture of our personal care line of business were used to prepay a portion of our Amended Term Loan Facility during the three-month period ended March 31, 2023.

The Third Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Third Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Third Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Third Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Third Amended Credit Agreement.

The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Third Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions.

As of September 30, 2023, we had no outstanding borrowings under our $550.0 million Revolving Credit Facility. Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 4.2% and 3.2% for the three and nine-month periods ended September 30, 2022, respectively. Our weighted average interest rate for borrowings under our Amended Term Loan Facility was 7.1% and 6.6% for the three and nine-month periods ended September 30, 2023, respectively, and 3.8% and 2.6% for the three and nine-month periods ended September 30, 2022, respectively.

As of September 30, 2023, our availability under our $550.0 million Revolving Credit Facility was $517.4 million as we have no outstanding borrowings and $32.6 million outstanding in letters of credit.

Joinder Agreements

In connection with the Compassionate Care Hospice ("CCH") acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the “CCH Joinder”), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Third Amended Credit Agreement), the Amended and Restated Security Agreement, dated as of June 29, 2018 (the “Amended and Restated Security Agreement”), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the “Amended and Restated Pledge Agreement”). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Third Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the “AseraCare Joinder"). In connection with the Contessa acquisition and the Second Amendment, we entered into a Joinder Agreement, dated as of September 3, 2021, pursuant to which Contessa and its subsidiaries and Asana Hospice ("Asana"), which we acquired on January 1, 2020, and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Second Amended Credit Agreement (now the Third Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the “Contessa and Asana Joinder,” and together with the CCH Joinder and the AseraCare Joinder, the “Joinders”).

Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries also guaranteed our obligations, whether now existing or arising after the respective effective dates of the Joinders, under the Third Amended Credit Agreement pursuant to the terms of the Joinders and the Third Amended Credit Agreement.

Finance Leases

Our outstanding finance leases totaling $27.5 million relate to leased equipment and fleet vehicles and bear interest rates ranging from 2.2% to 8.0%.

Effective January 1, 2023, the master lease agreement for our fleet leases was modified to remove the residual value guarantee provided by the lessor on each of our fleet leases. The modification resulted in a change in the classification of our fleet leases from operating leases to finance leases. In connection with the modification, we reclassified approximately $15 million from the operating lease asset and liability accounts to the property and equipment and current/long-term obligations accounts within our condensed consolidated balance sheet. Additionally, following the modification, expenses associated with our fleet leases will now be recorded in depreciation expense and interest expense within our condensed consolidated statement of operations as opposed to cost of service and general and administrative expenses, which is where the expenses were reflected in prior periods.

6. COMMITMENTS AND CONTINGENCIES

Legal Proceedings - Ongoing

We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.

Legal fees related to all legal matters are expensed as incurred.

Third Party Audits - Ongoing

From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (“RACs”), Zone Program Integrity Contractors (“ZPICs”), Uniform Program Integrity Contractors (“UPICs”), Program Safeguard Contractors (“PSCs”), Medicaid Integrity Contractors (“MICs”), Supplemental Medical Review Contractors (“SMRCs”) and the Office of the Inspector General (“OIG”), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.

In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January 1, 2008 through March 31, 2010 (the “Review Period”) to determine whether the underlying services met pertinent Medicare payment requirements. We acquired the hospice operations subject to this review on August 1, 2009; the Review Period covered time periods both before and after our ownership of these hospice operations. Based on the ZPIC’s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June 6, 2011, the Medicare Administrative Contractor (“MAC”) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We disputed these findings, and our Florence subsidiary filed appeals through the Original Medicare Standard Appeals Process, in which we sought to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January 18, 2016, we received a letter dated January 6, 2016 referencing the ALJ hearing decision for the overpayment issued on June 6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million, including interest, based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid. No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of September 30, 2023, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August 1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

was $2.8 million. This amount is recorded as an indemnity receivable within other assets in our condensed consolidated balance sheets.

In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (“SafeGuard”), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covered time periods both before and after our ownership of the care centers, which were acquired on December 31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters were based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate.

As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers was reduced to $26.0 million, and the alleged overpayment for the Clearwater Care Center was reduced to $3.3 million. The Company filed Level III Administrative Appeals, and the ALJ hearings regarding the Lakeland Request for Repayment and the Clearwater Request for Repayment were held in April 2022. The Company received the results of the ALJ hearings in June 2022. The ALJ decisions for both the Clearwater Care Center and the Lakeland Care Centers were partially favorable for the claims that were reviewed, but the extrapolations were upheld. As a result, we increased our total accrual related to these matters from $17.4 million to $25.2 million, excluding interest. The repayment for the Lakeland Care Centers totaling $34.3 million ($22.8 million extrapolated repayment plus $11.5 million accrued interest) was made during the three-month period ended September 30, 2022. The repayment for the Clearwater Care Center totaling $3.7 million ($2.4 million extrapolated repayment plus $1.2 million accrued interest) was made during the three-month period ended December 31, 2022. Additionally, during the three-month period ended September 30, 2022, we wrote off $1.5 million of receivables that were impacted by these matters. We expect to be indemnified by the prior owners, upon exhaustion of the parties' appeal rights, for approximately $10.9 million and have recorded this amount within other assets in our condensed consolidated balance sheets as of September 30, 2023 and December 31, 2022.

Insurance

We are obligated for certain costs associated with our insurance programs, including employee health, workers’ compensation, professional liability and fleet. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.

Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers’ compensation insurance has a retention limit of $2.0 million per incident. Our professional liability insurance has a retention limit of $0.3 million per incident. Our fleet insurance has an exposure limit of $0.4 million per accident.

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

7. SEGMENT INFORMATION

Our operations involve servicing patients through our three reportable business segments: home health, hospice and high acuity care. We divested our personal care business on March 31, 2023. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provided patients with assistance with the essential activities of daily living. Our high acuity care segment delivers the essential elements of inpatient hospital, palliative and SNF care to patients in their homes. The “other” column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.

In connection with our reorganization initiatives, management has revised its measurement of our reportable segments' operating income (loss). Effective January 1, 2023, we transitioned corporate functions that were previously included within our high acuity care segment to the corporate support function in order to realize operational efficiencies. Additionally, effective January 1, 2023, we transitioned from the high acuity care segment to the home health segment the operations of a home health care center that was contributed to the high acuity care segment by one of our health system partners during 2022. Prior periods have been recast to conform to the current year presentation.

Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company’s chief operating decision maker and therefore are not disclosed below (amounts in millions).

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)


	For the Three-Month Period Ended September 30, 2023
	Home Health		Hospice		Personal Care		High Acuity Care		Other		Total
Net service revenue	$	351.6	$	200.2	$	—	$	4.4	$	—	$	556.2
Cost of service, inclusive of depreciation	201.6		104.2		—		5.8		—		311.6
General and administrative expenses	91.4		48.4		—		5.3		52.9		198.0
Depreciation and amortization	1.8		0.8		—		0.7		1.1		4.4
Operating expenses	294.8		153.4		—		11.8		54.0		514.0
Operating income (loss)	$	56.8	$	46.8	$	—	$	(7.4)	$	(54.0)	$	42.2

	For the Three-Month Period Ended September 30, 2022
	Home Health		Hospice		Personal Care		High Acuity Care		Other		Total
Net service revenue	$	339.2	$	198.7	$	16.6	$	3.5	$	—	$	558.0
Cost of service	196.7		109.4		12.2		3.9		—		322.2
General and administrative expenses	89.1		49.1		2.4		5.2		42.6		188.4
Depreciation and amortization	0.9		0.5		—		0.8		3.3		5.5
Investment impairment	—		—		—		3.0		—		3.0
Operating expenses	286.7		159.0		14.6		12.9		45.9		519.1
Operating income (loss)	$	52.5	$	39.7	$	2.0	$	(9.4)	$	(45.9)	$	38.9

	For the Nine-Month Period Ended September 30, 2023
	Home Health		Hospice		Personal Care		High Acuity Care		Other		Total
Net service revenue	$	1,044.7	$	592.8	$	15.0	$	13.1	$	—	$	1,665.6
Cost of service, inclusive of depreciation	593.1		304.4		11.1		15.5		—		924.1
General and administrative expenses	270.5		144.1		2.3		15.0		173.6		605.5
Depreciation and amortization	4.3		2.2		—		2.3		4.8		13.6
Operating expenses	867.9		450.7		13.4		32.8		178.4		1,543.2
Operating income (loss)	$	176.8	$	142.1	$	1.6	$	(19.7)	$	(178.4)	$	122.4

	For the Nine-Month Period Ended September 30, 2022
	Home Health		Hospice		Personal Care		High Acuity Care		Other		Total
Net service revenue	$	1,016.8	$	590.2	$	45.5	$	8.6	$	—	$	1,661.1
Cost of service	576.6		323.2		34.5		9.0		—		943.3
General and administrative expenses	261.1		152.1		6.8		14.6		126.0		560.6
Depreciation and amortization	3.3		1.7		0.1		2.4		12.2		19.7
Investment impairment	—		—		—		3.0		—		3.0
Operating expenses	841.0		477.0		41.4		29.0		138.2		1,526.6
Operating income (loss)	$	175.8	$	113.2	$	4.1	$	(20.4)	$	(138.2)	$	134.5

AMEDISYS, INC. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

8. SHARE REPURCHASES

On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we could repurchase up to $100 million of our outstanding common stock through December 31, 2022 (the "2022 Share Repurchase Program").

Under the terms of the 2022 Share Repurchase Program, we were allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases were determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. Pursuant to this program, we repurchased 150,000 shares of our common stock at a weighted average price of $115.64 per share and a total cost of approximately $17 million during the nine-month period ended September 30, 2022. The repurchased shares were classified as treasury shares. The 2022 Share Repurchase Program expired on December 31, 2022.

On February 2, 2023, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100 million of our outstanding common stock through December 31, 2023 (the "2023 Share Repurchase Program").

Under the terms of the 2023 Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. Effective January 1, 2023, repurchases are subject to a 1% excise tax under the Inflation Reduction Act. We have not repurchased any shares under the 2023 Share Repurchase Program as of September 30, 2023, and the Merger Agreement limits our ability to repurchase shares of our common stock prior to the completion of the Merger, subject to certain exceptions.

9. RELATED PARTY TRANSACTIONS

We have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. We incurred costs of approximately $3.0 million and $8.3 million during the three and nine-month periods ended September 30, 2023, respectively, and $2.4 million and $7.1 million during the three and nine-month periods ended September 30, 2022, respectively, in connection with our usage of Medalogix's analytics platforms.

We have an investment in a home health benefit manager, which is accounted for under the cost method. We incurred costs of approximately $0.3 million and $0.4 million during the three and nine-month periods ended September 30, 2023, respectively, in connection with our usage of the home health benefit manager's services.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations and financial condition for the three and nine-month periods ended September 30, 2023. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included herein, and the consolidated financial statements and notes and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 16, 2023 (the “Form 10-K”). Historical results that appear in the condensed consolidated financial statements should not be interpreted as being indicative of future operations.

Unless otherwise provided, “Amedisys,” “we,” “our,” and “the Company” refer to Amedisys, Inc. and our consolidated subsidiaries.

Overview

We are a provider of high-quality in-home healthcare and related services to the chronic, co-morbid, aging American population with approximately 73% of our consolidated net service revenue derived from Medicare for the three and nine-month periods ended September 30, 2023 and approximately 74% of our consolidated net service revenue derived from Medicare for the three and nine-month periods ended September 30, 2022.

Our operations involve servicing patients through our three reportable business segments: home health, hospice and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Our hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Our high acuity care segment delivers the essential elements of inpatient hospital, palliative and skilled nursing facility ("SNF") care to patients in their homes. As of September 30, 2023, we owned and operated 346 Medicare-certified home health care centers, 165 Medicare-certified hospice care centers and 10 admitting high acuity care joint ventures in 37 states within the United States and the District of Columbia. We divested our personal care business on March 31, 2023. Prior to that date, we reported the personal care business as a fourth operating segment.

Care Centers Summary (Includes Unconsolidated Joint Ventures)


	Home Health	Hospice	Personal Care	High Acuity Care (1)
As of December 31, 2022	347	164	13	8
Acquisitions/Startups/De Novos	2	1	—	2
Divestitures/Closures/Consolidations	(3)	—	(13)	—
As of September 30, 2023	346	165	—	10

(1) We have 10 admitting high acuity care joint ventures, which operate in 11 markets.

Recent Developments

Proposed Merger

On June 26, 2023, Amedisys, UnitedHealth Group Incorporated, a Delaware corporation ("UnitedHealth Group"), and Aurora Holdings Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"), entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which Merger Sub will merge with and into Amedisys with Amedisys continuing as the surviving corporation and becoming a wholly owned subsidiary of UnitedHealth Group (the “Merger”).

expiration or termination of the applicable waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; (iii) the receipt of the required state regulatory approvals; (iv) the absence of any law or order that has the effect of enjoining or otherwise prohibiting the completion of the Merger; and (v) the expiration or early termination of the waiting period (and any extension thereof) applicable to the consummation of the transactions contemplated by the Merger Agreement under all applicable antitrust laws without the imposition by any governmental entity of any term, condition, obligation, requirement, limitation, prohibition, remedy, sanction or other action that has resulted in or would reasonably be expected to result in a Burdensome Condition (as defined in the Merger Agreement). Due to these conditions and other contingencies, there can be no assurance that the Merger will be successfully completed. During the periods prior to and including the date of the closing of the Merger, we expect to incur significant additional merger-related expenses. See Part II, Item 1A. “Risk Factors.”

Termination of Option Care Heath, Inc. ("OPCH") Merger Agreement

As previously disclosed in Amedisys’ Current Report on Form 8-K filed with the SEC on May 3, 2023 and its Quarterly Report on Form 10-Q filed with the SEC on May 4, 2023, Amedisys entered into an Agreement and Plan of Merger on May 3, 2023 (the “OPCH Merger Agreement”) with OPCH, a Delaware corporation, and Uintah Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of OPCH (“OPCH Merger Sub”). On June 26, 2023, Amedisys, OPCH and OPCH Merger Sub entered into the Termination Agreement (the “Termination Agreement”), pursuant to which the parties thereto agreed to terminate the OPCH Merger Agreement and grant mutual releases by the parties of all claims against the other parties based upon, arising from, in connection with or relating to the OPCH Merger Agreement. Pursuant to the terms of the Termination Agreement, each of the termination of the OPCH Merger Agreement and the mutual releases provided for in the Termination Agreement would become effective upon receipt by OPCH of a $106,000,000 termination fee payable by, or on behalf of, Amedisys within 24 hours of the execution of the Termination Agreement (i.e., before the market open on June 27, 2023). On June 26, 2023, following the execution of the Termination Agreement, UnitedHealth Group, on behalf of Amedisys, delivered funds to OPCH in an amount equal to $106,000,000, representing the termination fee payable to OPCH under the OPCH Merger Agreement and the Termination Agreement, satisfying the condition precedent to the effectiveness of the termination of the OPCH Merger Agreement and the releases contained in the Termination Agreement. If the Merger Agreement is terminated under certain specified circumstances, Amedisys may be required to reimburse UnitedHealth Group for the $106,000,000 termination fee that UnitedHealth Group, on Amedisys’ behalf, paid to OPCH in addition to the $125,000,000 termination fee payable by Amedisys to UnitedHealth Group upon termination of the Merger Agreement. The $106,000,000 termination fee was recorded to other income (expense) within our condensed consolidated statement of operations with a corresponding liability to termination fee paid by UnitedHealth Group within our condensed consolidated balance sheet during the three-month period ended June 30, 2023.

Executive Leadership

On March 13, 2023, our Board of Directors named Richard Ashworth as the Company’s President and Chief Executive Officer and elected Mr. Ashworth as a director, all effective April 10, 2023. Mr. Ashworth will not serve on any committees of the Board of Directors. Paul B. Kusserow ceased serving as Chief Executive Officer effective April 10, 2023 but continues to serve as Chairman of the Board.

Personal Care Divestiture

The Centers for Medicare and Medicaid Services ("CMS") Payment Updates

Hospice

On July 27, 2022, CMS issued the final rule to update hospice payment rates and the wage index for fiscal year 2023, effective for services provided beginning October 1, 2022. CMS estimated hospices serving Medicare beneficiaries would see a 3.8% increase in payments. This increase is the result of a 4.1% market basket adjustment as required under the Patient Protection and Affordable Health Care Act and the Health Care and Education Reconciliation Act ("PPACA") less a 0.3% productivity adjustment. Additionally, CMS increased the aggregate cap amount by 3.8% to $32,487. Based on our analysis of the final rule, we expect our impact to be in line with the 3.8% increase.

On July 28, 2023, CMS issued the final rule to update hospice payment rates and the wage index for fiscal year 2024, effective for services provided beginning October 1, 2023. CMS estimates hospices serving Medicare beneficiaries will see a 3.1% increase in payments. This increase is the result of a 3.3% market basket adjustment as required under PPACA less a 0.2% productivity adjustment. Additionally, CMS increased the aggregate cap amount by 3.1% to $33,494. Based on our analysis of the final rule, we expect our impact to be in line with the 3.1% increase.

Home Health

On October 31, 2022, CMS issued the Calendar Year ("CY") 2023 Final Rule for Medicare home health providers. CMS estimated that the final rule would result in a 0.7% increase in payments to home health providers. This increase is the result of a 4.0% payment update (4.1% market basket adjustment less a 0.1% productivity adjustment) and an increase of 0.2% for the update to the fixed-dollar loss ratio used in determining outlier payments offset by a permanent adjustment of -3.5% based on the difference between assumed and actual behavioral changes resulting from the implementation of PDGM. The -3.5% adjustment was derived from a -3.925% permanent adjustment which was only applied to the 30-day payment rate and not the low utilization payment adjustment. The -3.925% adjustment was only half of the total proposed adjustment of -7.85%. The remaining -3.925% adjustment was to be considered in future rulemaking. The final rule also finalized a permanent 5% cap on negative wage index changes for home health agencies. Based on our analysis of the final rule, we expect our impact to be flat, which is less than the estimated 0.7% rate increase.

On June 30, 2023, CMS issued the CY 2024 Proposed Rule for Medicare home health providers. CMS estimates that the proposed rule will result in a 2.2% decrease in payments to home health providers. This decrease is the result of a 2.7% payment update (3.0% market basket adjustment less a 0.3% productivity adjustment) and an increase of 0.2% for the update to the fixed-dollar loss ratio used in determining outlier payments offset by a permanent adjustment of -5.1% (which includes the remaining -3.925% permanent adjustment not applied to the calendar year 2023 payment rate). We expect CMS to release the Final Rule during the fourth quarter.

In addition to the permanent adjustments, CMS also has discretion to make temporary adjustments through calendar year 2026; however, CMS has elected not to implement a temporary adjustment for calendar year 2024.

On July 5, 2023, the National Association for Home Care and Hospice ("NAHC"), the leading national home health trade association, filed suit against CMS in the United States District Court for the District of Columbia over the implementation of the payment cuts CMS made in the CY 2023 Final Rule; that litigation remains pending.

Sequestration

In March 2020, Congress passed the bipartisan Coronavirus Aid, Relief and Economic Security Act ("CARES Act") which provided for the suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1, 2020 through December 31, 2020. During 2020 and 2021, Congress passed additional COVID-19 relief legislation which extended the 2% suspension of sequestration through March 31, 2022; sequestration was reinstated as a 1% reduction to Medicare claim reimbursements for the period April 1, 2022 through June 30, 2022 and was fully reinstated as a 2% reduction to Medicare claim reimbursements effective July 1, 2022. The reinstatement of sequestration has resulted in a reduction of our net service revenue.

Results of Operations

Three-Month Period Ended September 30, 2023 Compared to the Three-Month Period Ended September 30, 2022

Consolidated

The following table summarizes our consolidated results of operations (amounts in millions):


	For the Three-Month Periods Ended September 30,
	2023			2022
Net service revenue	$	556.2		$	558.0
Cost of service, inclusive of depreciation	311.6			322.2
Gross margin	244.6			235.8
% of revenue	44.0		%	42.3		%
General and administrative expenses	198.0			188.4
% of revenue	35.6		%	33.8		%
Depreciation and amortization	4.4			5.5
Investment impairment	—			3.0
Operating income	42.2			38.9
Total other expense	(4.3)			(4.1)
Income tax expense	(12.3)			(9.4)
Effective income tax rate	32.5		%	27.0		%
Net income	25.6			25.4
Net loss attributable to noncontrolling interests	0.3			0.2
Net income attributable to Amedisys, Inc.	$	26.0		$	25.6

On a consolidated basis, our operating income increased $3 million on a $2 million decrease in net service revenue. Our year-over-year results were impacted by merger-related expenses totaling $5 million, higher incentive compensation costs totaling $11 million with $7 million due to a reversal of accruals in the prior year based on performance, the divestiture of our personal care line of business (which contributed $17 million in revenue and operating income of $2 million in the prior year), a $3 million impairment charge recorded in the prior year in connection with the wind down of operations of one of our high acuity care joint ventures and a $1 million reduction in net service revenue in the prior year related to our Infinity Home Care, L.L.C. Zone Program Integrity Contractor ("Infinity ZPIC") audits (see Note 6 - Commitments and Contingencies to our condensed consolidated financial statements for additional information regarding the Infinity ZPIC).

Excluding these items, our operating income increased $17 million on a $14 million increase in net service revenue due to the hospice rate increase, home health volume growth and non-Medicare rate increases, savings associated with clinical optimization and reorganization initiatives, improvements in clinician utilization, a decrease in our general and administrative expenses and lower depreciation and amortization partially offset by lower hospice average daily census, a shift in our home health payor mix, planned wage increases and wage inflation.

Our operating results reflect a $10 million increase in our general and administrative expenses compared to the prior year. Excluding our merger-related expenses ($5 million), higher incentive compensation costs as described above ($11 million) and the divestiture of our personal care line of business ($2 million in the prior year), our general and administrative expenses decreased $4 million year over year primarily due to lower staffing levels, savings associated with clinical optimization and reorganization initiatives, lower travel and training spend and lower acquisition and integration costs. These items were partially offset by planned wage increases, higher information technology fees and a change in the presentation of gains on the sale of fleet vehicles which are reflected in other income (expense) within our condensed consolidated statement of operations as of January 1, 2023 due to the modification of our fleet leases.

Total other expense includes the following items (amounts in millions):


	For the Three-Month Periods Ended September 30,
	2023		2022
Interest income	$	1.3	$	0.1
Interest expense	(8.0)		(5.0)
Equity in earnings from equity method investments	1.2		0.3
Miscellaneous, net	1.2		0.5
Total other expense	$	(4.3)	$	(4.1)

Home Health Segment

The following table summarizes our home health segment results of operations:


	For the Three-Month Periods Ended September 30,
	2023			2022
Financial Information (in millions) (6):
Medicare	$	217.9		$	225.6
Non-Medicare	133.7			113.6
Net service revenue	351.6			339.2
Cost of service, inclusive of depreciation	201.6			196.7
Gross margin	150.0			142.5
General and administrative expenses	91.4			89.1
Depreciation and amortization	1.8			0.9
Operating income	$	56.8		$	52.5
Same Store Growth(1):
Medicare revenue	(2		%)	(6		%)
Non-Medicare revenue	17		%	(1		%)
Total admissions	4		%	5		%
Total volume(2)	3		%	1		%


Key Statistical Data - Total(3)(6):
Admissions	98,527			95,566
Recertifications	45,693			45,098
Total volume	144,220			140,664

Medicare completed episodes	72,714			76,334
Average Medicare revenue per completed episode(4)	$	3,015		$	2,992
Medicare visits per completed episode(5)	12.4			12.7

Visiting clinician cost per visit	$	105.06		$	101.33
Clinical manager cost per visit	11.98			11.44
Total cost per visit	$	117.04		$	112.77
Visits	1,723,289			1,744,385

(1)Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.

(2)Total volume includes all admissions and recertifications.

(3)Total includes acquisitions, startups and de novos.

(4)Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care.

(5)Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.

(6)Prior year has been recast to conform to the current year presentation.

Operating Results

On March 23, 2022, we entered into a transaction with one of our high acuity care health system partners in which our health system partner contributed its home health operations to one of our existing high acuity care joint ventures. The home health operations were reflected in our high acuity care segment during 2022. Effective January 1, 2023, the operating results of this home health care center are included within our home health segment. Prior periods have been recast to conform to the current year presentation.

Overall, our operating income increased $4 million on a $12 million increase in net service revenue. Our year over year results were impacted by higher incentive compensation costs totaling $3 million with $2 million due to a reversal of accruals in the prior year based on performance and a $1 million reduction in prior year net service revenue related to our Infinity ZPIC audits discussed above.

Excluding these items, our operating income increased $6 million on an $11 million increase in net service revenue as same store total volume growth, an improvement in our non-Medicare revenue per visit and improvement in our operating performance driven by improvements in clinician utilization were partially offset by a shift in our payor mix, planned wage increases and wage inflation.

Net Service Revenue

Our net service revenue increased $12 million. Excluding the prior year reduction in net service revenue related to the Infinity ZPIC discussed above, our net service revenue increased $11 million as a result of same store total volume growth of 3% and an increase in our non-Medicare revenue per visit resulting from rate increases partially offset by a shift in our payor mix. Our volumes continue to be impacted by staffing shortages driven by the competitive labor market.

Cost of Service, Inclusive of Depreciation

Our cost of service consists of costs associated with direct clinician care in the homes of our patients as well as the cost of clinical managers who monitor the overall delivery of care. Overall, our total cost of service increased 3% as a 4% increase in our total cost per visit was offset by a 1% decrease in total visits driven by improvements in clinician utilization evidenced by a decline of 0.3 visits per Medicare completed episode year over year. The 4% increase in our total cost per visit is primarily due to planned wage increases, an increase in new hire pay, wage inflation and visit mix.

General and Administrative Expenses

Our general and administrative expenses increased $2 million. Excluding the $3 million increase in incentive compensation costs described above, our general and administrative expenses decreased $1 million year over year due to lower staffing levels and savings associated with clinical optimization and reorganization initiatives partially offset by planned wage increases and higher information technology fees.

Hospice Segment

The following table summarizes our hospice segment results of operations:


	For the Three-Month Periods Ended September 30,
	2023			2022
Financial Information (in millions):
Medicare	$	188.9		$	187.8
Non-Medicare	11.3			10.9
Net service revenue	200.2			198.7
Cost of service, inclusive of depreciation	104.2			109.4
Gross margin	96.0			89.3
General and administrative expenses	48.4			49.1
Depreciation and amortization	0.8			0.5
Operating income	$	46.8		$	39.7
Same Store Growth(1):
Medicare revenue	1		%	—		%
Hospice admissions	(6		%)	(3		%)
Average daily census	(2		%)	1		%
Key Statistical Data - Total(2):
Hospice admissions	11,968			12,782
Average daily census	12,943			13,314
Revenue per day, net	$	168.11		$	162.24
Cost of service per day	$	87.48		$	89.36
Average discharge length of stay	94			92

(1)Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.

(2)Total includes acquisitions and de novos.

Operating Results

Overall, our operating income increased $7 million on a $2 million increase in net service revenue. Our year over year results were impacted by higher incentive compensation costs totaling $1 million due to a reversal of accruals in the prior year based on performance. Excluding this item, our operating income increased $8 million on a $2 million increase in net service revenue primarily due to the increase in reimbursement effective October 1, 2022, savings associated with clinical optimization and reorganization initiatives and a decrease in our general and administrative expenses. These items were partially offset by a decline in our hospice average daily census, planned wage increases and wage inflation.

Net Service Revenue

Our net service revenue increased $2 million as the increase in reimbursement effective October 1, 2022 was offset by a decline in our average daily census. The decline in our average daily census year over year is primarily due to a decline in our hospice admissions as well as care center closures.

Cost of Service, Inclusive of Depreciation

Our hospice cost of service decreased 5% primarily due to a 2% decrease in our cost of service per day and a 3% decline in our total average daily census. The decrease in our cost of service per day is due to savings associated with clinical optimization and reorganization initiatives, a new pharmacy contract effective during the three-month period ended June 30, 2023 and lower general inpatient and supplies costs. These items were partially offset by planned wage increases and wage inflation.

General and Administrative Expenses

Excluding the $1 million increase in our incentive compensation costs described above, our general and administrative expenses decreased $2 million primarily due to lower staffing levels and lower travel and training spend partially offset by planned wage increases.

Personal Care Segment

The following table summarizes our personal care segment results of operations:


	For the Three-Month Periods Ended September 30,
	2023		2022
Financial Information (in millions):
Medicare	$	—	$	—
Non-Medicare	—		16.6
Net service revenue	—		16.6
Cost of service, inclusive of depreciation	—		12.2
Gross margin	—		4.4
General and administrative expenses	—		2.4
Depreciation and amortization	—		—
Operating income	$	—	$	2.0
Key Statistical Data - Total:
Billable hours	—		474,365
Clients served	—		7,771
Shifts	—		202,638
Revenue per hour	$	—	$	34.98
Revenue per shift	$	—	$	81.89
Hours per shift	—		2.3

Operating Results

We completed the sale of our personal care business on March 31, 2023.

High Acuity Care Segment

The following table summarizes our high acuity care segment results of operations:


	For the Three-Month Periods Ended September 30,
	2023		2022
Financial Information (in millions) (1):
Medicare	$	—	$	—
Non-Medicare	4.4		3.5
Net service revenue	4.4		3.5
Cost of service, inclusive of depreciation	5.8		3.9
Gross margin	(1.4)		(0.4)
General and administrative expenses	5.3		5.2
Depreciation and amortization	0.7		0.8
Investment impairment	—		3.0
Operating loss	$	(7.4)	$	(9.4)
Key Statistical Data - Total:
Full risk admissions	150		130
Limited risk admissions	430		300
Total admissions	580		430

Full risk revenue per episode	$	10,168	$	11,615
Limited risk revenue per episode	$	6,242	$	5,580

Number of admitting joint venture markets	11		8

(1)Prior year has been recast to conform to the current year presentation.

Operating Results

In connection with our reorganization initiatives, we transitioned corporate functions that were previously included within our high acuity care segment to the corporate support function effective January 1, 2023. Additionally, we moved the home health operations of one of our high acuity care joint ventures to our home health segment effective January 1, 2023. Prior periods have been recast to conform to the current year presentation.

Our year over year results reflect growth in our home recovery care services which was offset by an increase in our cost of service. Our cost of service for the three-month period ended September 30, 2023 reflects investments in resources to support the first performance year of our new risk-based palliative care contract as well as future palliative care arrangements. Additionally, prior year results include an impairment charge recorded in connection with the wind down of the operations of one of our joint ventures.

Although we expect our high acuity care segment to continue to generate operating losses, we also expect improvement as we leverage our operating structure through growth in current and future joint ventures and expansion of palliative care at home arrangements.

Net Service Revenue

Our high acuity care segment provides home recovery care services for high acuity patients on either a full risk or limited risk basis, each with different reimbursement arrangements. Full risk admissions are admissions for which we assume the financial risk for all related healthcare services during a 30-day or 60-day episodic period in exchange for a fixed contracted bundled rate. Limited risk admissions are admissions for which we assume the risk for certain healthcare services during a shorter acute phase period (equivalent to an inpatient hospital stay) in exchange for a contracted per diem payment.

Cost of Service, Inclusive of Depreciation

Our cost of service consists primarily of medical costs associated with direct clinician care provided to our patients during the applicable episode period, costs associated with our virtual care unit (“VCU”) which enables us to provide monitoring services and facilitates virtual patient rounding visits via telehealth and costs associated with resources to support our new risk-based palliative care at home contract as well as other palliative care arrangements. The increase in cost of service over prior year is primarily related to growth in our home recovery care services and investments in resources to support the first performance year of our new risk-based palliative care contract as well as future palliative care programs.

General and Administrative Expenses

Our general and administrative expenses, which primarily consist of salaries and benefits, were flat year over year. We have made significant investments to build the clinical, operational and technological infrastructure necessary to support the development and future growth of home recovery care and palliative care programs on a national scale.

Corporate

The following table summarizes our corporate results of operations:


	For the Three-Month Periods Ended September 30,
	2023		2022
Financial Information (in millions) (1):
General and administrative expenses	$	52.9	$	42.6
Depreciation and amortization	1.1		3.3
Total operating expenses	$	54.0	$	45.9

(1)Prior year has been recast to conform to the current year presentation.

Corporate expenses consist of costs related to our executive management and corporate and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.

Corporate general and administrative expenses increased $10 million during the three-month period ended September 30, 2023, which is inclusive of merger-related expenses totaling $5 million and higher incentive compensation costs totaling $7 million with $4 million due to a reversal of accruals in the prior year based on performance. Excluding these costs, our corporate general and administrative expenses decreased $2 million primarily due to lower acquisition and integration costs and lower staffing levels. These items were partially offset by planned wage increases and a change in the presentation of gains on the sale of fleet vehicles which are reflected in other income (expense) within our condensed consolidated statement of operations as of January 1, 2023 due to the modification of our fleet leases.

Corporate depreciation and amortization decreased $2 million during the three-month period ended September 30, 2023 due to a reduction in amortization expense related to acquired names and non-compete agreements that were fully amortized as of December 31, 2022.

Nine-Month Period Ended September 30, 2023 Compared to the Nine-Month Period Ended September 30, 2022

Consolidated

The following table summarizes our consolidated results of operations (amounts in millions):


	For the Nine-Month Periods Ended September 30,
	2023			2022
Net service revenue	$	1,665.6		$	1,661.1
Cost of service, inclusive of depreciation	924.1			943.3
Gross margin	741.5			717.8
% of revenue	44.5		%	43.2		%
General and administrative expenses	605.5			560.6
% of revenue	36.4		%	33.7		%
Depreciation and amortization	13.6			19.7
Investment impairment	—			3.0
Operating income	122.4			134.5
Total other expense	(112.0)			(15.6)
Income tax expense	(40.4)			(32.8)
Effective income tax rate	387.3		%	27.5		%
Net (loss) income	(30.0)			86.2
Net loss attributable to noncontrolling interests	0.9			0.7
Net (loss) income attributable to Amedisys, Inc.	$	(29.1)		86.9

On a consolidated basis, our operating income decreased $12 million on a $5 million increase in net service revenue. Our year-over-year results were impacted by merger-related expenses totaling $25 million, higher incentive compensation costs totaling $15 million resulting primarily from the reversal of accruals in the prior year based on performance and higher field incentive payouts in the current year, the return of sequestration (prior year included a benefit of $13 million associated with the suspension of sequestration), the acquisitions of Evolution and AssistedCare on April 1, 2022 (which combined contributed $10 million in incremental revenue and an operating loss of $1 million to the current year), the divestiture of our personal care line of business (which contributed an incremental $30 million in revenue and $2 million in operating income in the prior year), a $3 million impairment charge recorded in the prior year in connection with the wind down of operations of one of our high acuity care joint ventures and a $9 million reduction to net service revenue in the prior year related to our Infinity ZPIC audits (see Note 6 - Commitments and Contingencies to our condensed consolidated financial statements for additional information regarding the Infinity ZPIC).

Excluding these items, our operating income increased $32 million on a $29 million increase in net service revenue due to the hospice rate increase, home health volume growth and non-Medicare rate increases, savings associated with clinical optimization and reorganization initiatives, improvements in clinician utilization, lower COVID-related costs and lower depreciation and amortization partially offset by lower hospice average daily census, a shift in our home health payor mix, planned wage increases, wage inflation and an increase in our general and administrative expenses.

Our operating results reflect a $45 million increase in our general and administrative expenses compared to the prior year. Excluding our merger-related expenses ($25 million), the general and administrative impact of the higher incentive compensation costs described above ($14 million), incremental expenses related to our acquisitions in the current year ($3 million) and our personal care line of business in the prior year ($4 million), our general and administrative expenses increased $7 million (1%) primarily due to planned wage increases, higher insurance-related costs, recruiting fees and information technology fees, a favorable legal settlement recognized in the prior year and a change in the presentation of gains on the sale of fleet vehicles which are reflected in other income (expense) within our condensed consolidated statement of operations as of January 1, 2023 due to the modification of our fleet leases. These items were partially offset by lower acquisition and integration costs, lower staffing levels, savings associated with clinical optimization and reorganization initiatives and lower travel and training spend.

Total other expense includes the following items (amounts in millions):


	For the Nine-Month Periods Ended September 30,
	2023		2022
Interest income	$	2.4	$	0.1
Interest expense	(23.0)		(16.4)
Equity in earnings (loss) from equity method investments	9.4		(0.4)
Merger termination fee	(106.0)		—
Miscellaneous, net	5.3		1.1
Total other expense	$	(112.0)	$	(15.6)

The merger termination fee represents the fee associated with Amedisys' termination of the OPCH Merger Agreement. The fee was paid by UnitedHealth Group on Amedisys' behalf. Amedisys may be required to reimburse UnitedHealth Group for the termination fee payment under certain circumstances (see Note 4 - Mergers, Acquisitions and Dispositions to our condensed consolidated financial statements for additional information).

Home Health Segment

The following table summarizes our home health segment results of operations:


	For the Nine-Month Periods Ended September 30,
	2023			2022
Financial Information (in millions) (6):
Medicare	$	653.1		$	671.7
Non-Medicare	391.6			345.1
Net service revenue	1,044.7			1,016.8
Cost of service, inclusive of depreciation	593.1			576.6
Gross margin	451.6			440.2
General and administrative expenses	270.5			261.1
Depreciation and amortization	4.3			3.3
Operating income	$	176.8		$	175.8
Same Store Growth(1):
Medicare revenue	(3		%)	(5		%)
Non-Medicare revenue	13		%	—		%
Total admissions	5		%	2		%
Total volume(2)	3		%	—		%


Key Statistical Data - Total(3)(6):
Admissions	297,943			281,393
Recertifications	134,826			133,775
Total volume	432,769			415,168

Medicare completed episodes	221,125			229,098
Average Medicare revenue per completed episode(4)	$	2,998		$	3,019
Medicare visits per completed episode(5)	12.4			13.0

Visiting clinician cost per visit	$	101.55		$	98.72
Clinical manager cost per visit	11.41			10.99
Total cost per visit	$	112.96		$	109.71
Visits	5,250,944			5,256,207

(2)Total volume includes all admissions and recertifications.

(3)Total includes acquisitions, startups and de novos.

(4)Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the suspension of sequestration at 2% and 1% for the for the three-month periods ended March 31, 2022 and June 30, 2022, respectively, and the reinstatement of sequestration at 2% effective July 1, 2022.

(5)Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.

(6)Prior year has been recast to conform to the current year presentation.

Operating Results

Overall, our operating income increased $1 million on a $28 million increase in net service revenue. Our year over year results were impacted by the April 1, 2022 acquisitions of Evolution and AssistedCare (which combined contributed $10 million in incremental net service revenue and an operating loss of $1 million to the current year), a prior year benefit of $7 million in connection with the suspension of sequestration, a $9 million reduction to net service revenue recorded in the prior year related to our Infinity ZPIC audits discussed above and higher incentive compensation costs totaling $5 million resulting primarily from the reversal of accruals in the prior year based on performance and higher field incentive payouts in the current year.

Excluding these items, our operating income increased $5 million on a $16 million increase in net service revenue. Our operating income was positively impacted by same store total volume growth, an increase in our non-Medicare revenue per visit and improvement in our operating performance driven by improvements in clinician utilization. These items were partially offset by a shift in our payor mix, planned wage increases, wage inflation and an increase in depreciation and amortization.

Net Service Revenue

Our net service revenue increased $28 million. Excluding our acquisitions, the sequestration benefit recognized in the prior year and the Infinity ZPIC discussed above, our net service revenue increased $16 million due to 3% same store total volume growth and an increase in our non-Medicare revenue per visit resulting from rate increases partially offset by a shift in our payor mix. Our volumes continue to be impacted by staffing shortages driven by the competitive labor market.

Cost of Service, Inclusive of Depreciation

Overall, our total cost of service increased 3% due to a 3% increase in our total cost per visit. The increase in our total cost per visit is primarily due to planned wage increases, an increase in new hire pay, wage inflation and visit mix partially offset by lower COVID-19 costs. Our visits year over year were relatively flat as increases in visits driven by growth in volumes were partially offset by improvements in clinician utilization evidenced by a decline of 0.6 visits per Medicare completed episode.

General and Administrative Expenses

Our general and administrative expenses increased $9 million. Excluding our acquisitions ($3 million) and the general and administrative impact of the higher incentive compensation costs described above ($4 million), our general and administrative expenses increased $2 million primarily due to planned wage increases, higher information technology fees and higher insurance-related costs partially offset by lower staffing levels, savings associated with clinical optimization and reorganization initiatives and lower travel and training spend.

Hospice Segment

The following table summarizes our hospice segment results of operations:


	For the Nine-Month Periods Ended September 30,
	2023			2022
Financial Information (in millions):
Medicare	$	559.8		$	557.8
Non-Medicare	33.0			32.4
Net service revenue	592.8			590.2
Cost of service, inclusive of depreciation	304.4			323.2
Gross margin	288.4			267.0
General and administrative expenses	144.1			152.1
Depreciation and amortization	2.2			1.7
Operating income	$	142.1		$	113.2
Same Store Growth(1):
Medicare revenue	—		%	—		%
Hospice admissions	(6		%)	1		%
Average daily census	(2		%)	(1		%)
Key Statistical Data - Total(2):
Hospice admissions	37,361			40,027
Average daily census	12,864			13,163
Revenue per day, net	$	168.80		$	164.24
Cost of service per day	$	86.66		$	89.94
Average discharge length of stay	91			90

(2)Total includes acquisitions and de novos.

Operating Results

Overall, our operating income increased $29 million on a $3 million increase in net service revenue. Our year over year results were impacted by a prior year benefit of $6 million related to the suspension of sequestration and higher incentive compensation costs totaling $1 million resulting primarily from the reversal of accruals in the prior year based on performance. Excluding these items, our operating income increased $36 million on a $9 million increase in net service revenue primarily due to the increase in reimbursement effective October 1, 2022, savings associated with clinical optimization and reorganization initiatives, lower staffing levels and a decrease in our general and administrative expenses. These items were partially offset by a decline in our hospice average daily census, planned wage increases and wage inflation.

Net Service Revenue

Our net service revenue increased $3 million. Excluding the sequestration benefit recognized in the prior year, our net service revenue increased $9 million as the increase in reimbursement effective October 1, 2022 was partially offset by a decline in our average daily census. The decline in our average daily census year over year is primarily due to a decline in our hospice admissions as well as care center closures.

Cost of Service, Inclusive of Depreciation

Our hospice cost of service decreased 6% primarily due to a 4% decrease in our cost of service per day and a 2% decline in our total average daily census. The 4% decrease in our cost of service per day is due to savings associated with clinical optimization and reorganization initiatives, lower utilization of contractors to supplement our staffing levels, lower COVID-19 costs and a new pharmacy contract effective during the three-month period ended June 30, 2023. These items were partially offset by planned wage increases and wage inflation.

General and Administrative Expenses

Our general and administrative expenses decreased $8 million. Excluding the impact of the higher incentive compensation costs described above, our general and administrative expenses decreased $9 million primarily due to reductions in staffing levels and lower travel and training spend partially offset by planned wage increases.

Personal Care Segment

The following table summarizes our personal care segment results of operations:


	For the Nine-Month Periods Ended September 30,
	2023		2022
Financial Information (in millions):
Medicare	$	—	$	—
Non-Medicare	15.0		45.5
Net service revenue	15.0		45.5
Cost of service, inclusive of depreciation	11.1		34.5
Gross margin	3.9		11.0
General and administrative expenses	2.3		6.8
Depreciation and amortization	—		0.1
Operating income	$	1.6	$	4.1
Key Statistical Data - Total:
Billable hours	440,464		1,397,919
Clients served	7,892		9,530
Shifts	191,379		598,376
Revenue per hour	$	33.97	$	32.53
Revenue per shift	$	78.19	$	76.00
Hours per shift	2.3		2.3

Operating Results

We completed the sale of our personal care business on March 31, 2023.

High Acuity Care Segment

The following table summarizes our high acuity care segment results of operations:


	For the Nine-Month Periods Ended September 30,
	2023		2022
Financial Information (in millions) (1):
Medicare	$	—	$	—
Non-Medicare	13.1		8.6
Net service revenue	13.1		8.6
Cost of service, inclusive of depreciation	15.5		9.0
Gross margin	(2.4)		(0.4)
General and administrative expenses	15.0		14.6
Depreciation and amortization	2.3		2.4
Investment impairment	—		3.0
Operating loss	$	(19.7)	$	(20.4)
Key Statistical Data - Total:
Full risk admissions	468		339
Limited risk admissions	1,263		768
Total admissions	1,731		1,107

Full risk revenue per episode	$	10,783	$	11,018
Limited risk revenue per episode	$	5,881	$	5,556
			8
Number of admitting joint venture markets	11		8

(1)Prior year has been recast to conform to the current year presentation.

Operating Results

Our year over year results reflect growth in our home recovery care services which was offset by an increase in our cost of service. Our cost of service for the nine-month period ended September 30, 2023 reflects investments in resources to support the first performance year of our new risk-based palliative care contract as well as future palliative care arrangements. Additionally, prior year results include an impairment charge recorded in connection with the wind down of the operations of one of our joint ventures.

Net Service Revenue

Cost of Service, Inclusive of Depreciation

Our cost of service consists primarily of medical costs associated with direct clinician care provided to our patients during the applicable episode period, costs associated with our virtual care unit (“VCU”), which enables us to provide monitoring services and facilitates virtual patient rounding visits via telehealth and costs associated with resources to support our new risk-based palliative care at home contract as well as other palliative care arrangements. The increase in cost of service over prior year is primarily related to growth in our home recovery care services and investments in resources to support the first performance year of our new risk-based palliative care contract as well as future palliative care programs.

General and Administrative Expenses

Our general and administrative expenses, which primarily consist of salaries and benefits, were relatively flat year over year. We have made significant investments to build the clinical, operational and technological infrastructure necessary to support the development and future growth of home recovery care and palliative care programs on a national scale.

Corporate

The following table summarizes our corporate results of operations:


	For the Nine-Month Periods Ended September 30,
	2023		2022
Financial Information (in millions) (1):
General and administrative expenses	$	173.6	$	126.0
Depreciation and amortization	4.8		12.2
Total operating expenses	$	178.4	$	138.2

(1)Prior year has been recast to conform to the current year presentation.

Corporate general and administrative expenses increased $48 million during the nine-month period ended September 30, 2023, which is inclusive of merger-related expenses totaling $25 million and higher incentive compensation costs totaling $9 million resulting primarily from the reversal of accruals in the prior year based on performance and new hire awards for our chief executive officer in the current year. Excluding these costs, our corporate general and administrative expenses increased $14 million primarily due to planned wage increases, higher recruiting fees and information technology fees, costs associated with our clinical optimization and reorganization initiatives, a favorable legal settlement recognized in the prior year and a change in the presentation of gains on the sale of fleet vehicles which are reflected in other income (expense) within our condensed consolidated statement of operations as of January 1, 2023 due to the modification of our fleet leases. These items were partially offset by lower acquisition and integration costs.

Corporate depreciation and amortization decreased $7 million during the nine-month period ended September 30, 2023 due to a reduction in amortization expense related to acquired names and non-compete agreements that were fully amortized as of December 31, 2022.

Liquidity and Capital Resources

Cash Flows

The following table summarizes our cash flows for the periods indicated (amounts in millions):


	For the Nine-Month Periods Ended September 30,
	2023		2022
Cash provided by operating activities	$	76.9	$	92.4
Cash provided by (used in) investing activities	37.1		(92.6)
Cash used in financing activities	(74.1)		(14.1)
Net increase (decrease) in cash, cash equivalents and restricted cash	39.9		(14.3)
Cash, cash equivalents and restricted cash at beginning of period	54.1		45.8
Cash, cash equivalents and restricted cash at end of period	$	94.0	$	31.5

Cash provided by operating activities decreased $15.5 million during the nine-month period ended September 30, 2023 compared to the nine-month period ended September 30, 2022 primarily due to the payment of merger-related expenses and delays in the billing and collection of outstanding accounts receivable resulting from payor rate changes during the third quarter. These items were partially offset by the timing of the payment of accrued expenses and a change in the presentation of payments associated with our fleet vehicles (financing activity in the current year versus operating activity in the prior year) due to the modification of our fleet leases effective January 1, 2023.

Our investing activities primarily consist of the purchase of property and equipment and technology assets, investments and acquisitions/divestitures. Cash provided by investing activities totaled $37.1 million during the nine-month period ended September 30, 2023 and was related to the divestiture of our personal care line of business partially offset by the purchase of software licenses and property and equipment. Cash used in investing activities totaled $92.6 million during the nine-month period ended September 30, 2022 and was primarily related to our purchase of Evolution and AssistedCare as well as a cost method investment.

Our financing activities primarily consist of borrowings under our term loan and/or revolving credit facility, repayments of borrowings, the remittance of taxes associated with shares withheld on non-cash compensation, proceeds related to the exercise of stock options, proceeds related to the purchase of stock under our employee stock purchase plan and our purchase of company stock under our stock repurchase program. Cash used in financing activities totaled $74.1 million and $14.1 million during the nine-month periods ended September 30, 2023 and 2022, respectively, and was primarily related to the repayment of borrowings, the remittance of taxes associated with shares withheld on non-cash compensation and payment of our accrued contingent consideration. Net proceeds from the divestiture of our personal care line of business were used to pay down a portion of our outstanding term loan borrowings during the three-month period ended March 31, 2023.

Liquidity

Typically, our principal source of liquidity is the collection of our patient accounts receivable, primarily through the Medicare program. In addition to our collection of patient accounts receivable, from time to time, we can and do obtain additional sources of liquidity by the incurrence of additional indebtedness.

During the nine-month period ended September 30, 2023, we spent $10.6 million in capital expenditures and technology assets as compared to $5.2 million during the nine-month period ended September 30, 2022. Our capital expenditures and investments in technology assets for 2023 are expected to be approximately $14.0 million to $15.0 million, excluding the impact of any future acquisitions.

As of September 30, 2023, we had $78.1 million in cash and cash equivalents and $517.4 million in availability under our $550.0 million Revolving Credit Facility.

Based on our operating forecasts and our debt service requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt service requirements for the next twelve months and beyond.

Outstanding Patient Accounts Receivable

Our patient accounts receivable increased $23 million from December 31, 2022 primarily due to delays in billing resulting from payor rate changes during the third quarter. Our cash collection as a percentage of revenue was 100% for the nine-month periods ended September 30, 2023 and 2022. Our days revenue outstanding at September 30, 2023 was 49.8 days, which is an increase of 3.7 days from December 31, 2022 and an increase of 2.5 days when compared to September 30, 2022.

Our patient accounts receivable includes unbilled receivables and are aged based upon our initial service date. We monitor unbilled receivables on a care center by care center basis to ensure that all efforts are made to bill claims within timely filing deadlines. Our unbilled patient accounts receivable can be impacted by pre-claim reviews required by the Medicare Administrative Contractors in the five Review Choice Demonstration states or under the Targeted Probe and Educate program, voluntary pre-bill edits and reviews, efforts to secure needed documentation to bill (orders, consents, etc.), integrations of recent acquisitions, changes of ownership and any regulatory and procedural updates impacting claim submissions. The timely filing deadline for Medicare is one year from the date of the last billable service in the 30-day billing period and varies by state for Medicaid-reimbursable services and among insurance companies and other private payors.

The following schedules detail our patient accounts receivable, by payor class, aged based upon initial date of service (amounts in millions, except days revenue outstanding):


	0-90		91-180		181-365		Over 365		Total
At September 30, 2023:
Medicare patient accounts receivable	$	180.1	$	19.5	$	5.7	$	1.9	$	207.2
Other patient accounts receivable:
Medicaid	18.6		1.3		0.7		—		20.6
Private	80.5		6.8		4.5		—		91.8
Total	$	99.1	$	8.1	$	5.2	$	—	$	112.4
Total patient accounts receivable									$	319.6
Days revenue outstanding (1)									49.8
	0-90		91-180		181-365		Over 365		Total
At December 31, 2022:
Medicare patient accounts receivable	$	179.9	$	11.4	$	5.1	$	0.1	$	196.5
Other patient accounts receivable:
Medicaid	16.3		1.4		0.7		—		18.4
Private	67.5		8.7		5.7		—		81.9
Total	$	83.8	$	10.1	$	6.4	$	—	$	100.3
Total patient accounts receivable									$	296.8
Days revenue outstanding (1)									46.1

(1)Our calculation of days revenue outstanding is derived by dividing our ending patient accounts receivable at September 30, 2023 and December 31, 2022 by our average daily net service revenue for the three-month periods ended September 30, 2023 and December 31, 2022, respectively.

Indebtedness

Second Amendment to the Credit Agreement

Third Amendment to the Credit Agreement

In accordance with the requirements under our Third Amended Credit Agreement, net proceeds received from the divestiture of our personal care line of business were used to prepay a portion of our Amended Term Loan Facility during the three-month period ended March 31, 2023.

As of September 30, 2023, our consolidated leverage ratio was 2.5, our consolidated interest coverage ratio was 5.5 and we are in compliance with our covenants under the Third Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.

See Note 5 - Long Term Obligations to our condensed consolidated financial statements for additional details on our outstanding long-term obligations.

Stock Repurchase Program

Inflation

Our operations have been materially impacted by the current inflationary environment as we have experienced higher labor costs and increases in supply costs, fuel costs and mileage reimbursements. We expect inflation to continue to impact our operations throughout 2023. As of September 30, 2023, the impacts of inflation on our results of operations have been partially

mitigated by rate increases, improvements in clinician utilization, reductions in hospice staffing levels and clinical optimization and reorganization initiatives. No assurance can be given as to our ability to offset the impacts of inflation in the future.

Critical Accounting Estimates

See Part II, Item 7 – Critical Accounting Estimates and our consolidated financial statements and related notes in Part II, Item 8 of our 2022 Annual Report on Form 10-K for accounting policies and related estimates we believe are the most critical to understanding our condensed consolidated financial statements, financial condition and results of operations and which require complex management judgment and assumptions or involve uncertainties. These critical accounting estimates include revenue recognition, business combinations and goodwill and other intangible assets. There have not been any changes to our significant accounting policies or their application since we filed our 2022 Annual Report on Form 10-K.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk from fluctuations in interest rates. Our Term Loan and Revolving Credit Facility carry a floating interest rate which is tied to the Secured Overnight Financing Rate ("SOFR") and the Prime Rate, and therefore, our condensed consolidated statements of operations and our condensed consolidated statements of cash flows are exposed to changes in interest rates. As of September 30, 2023, the total amount of outstanding debt subject to interest rate fluctuations was $377.5 million. A 1.0% interest rate change would cause interest expense to change by approximately $3.8 million annually, assuming the Company makes no principal repayments.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We have established disclosure controls and procedures which are designed to provide reasonable assurance of achieving their objectives and to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized, disclosed and reported within the time periods specified in the SEC's rules and forms. This information is also accumulated and communicated to our management and Board of Directors to allow timely decisions regarding required disclosure.

In connection with the preparation of this Quarterly Report on Form 10-Q, as of September 30, 2023, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act.

Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of September 30, 2023, the end of the period covered by this Quarterly Report.

Changes in Internal Controls

There have been no changes in our internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) that have occurred during the quarter ended September 30, 2023, that have materially impacted, or are reasonably likely to materially impact, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls’ effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and, based on an evaluation of our controls and procedures, our principal executive officer and our principal financial officer concluded our disclosure controls and procedures were effective at a reasonable assurance level as of September 30, 2023, the end of the period covered by this Quarterly Report.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Note 6 - Commitments and Contingencies to the condensed consolidated financial statements for information concerning our legal proceedings.

ITEM 1A. RISK FACTORS

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022. These risks, which could materially affect our business, financial condition or future results, are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may adversely affect our business, financial condition and/or operating results.

In addition to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022, the following risks are related to the proposed Merger with UnitedHealth Group:

The proposed Merger is subject to the satisfaction of certain closing conditions, including government consents and approvals, some or all of which may not be satisfied or completed within the expected timeframe, if at all.

Completion of the Merger is subject to a number of closing conditions, including obtaining the approval of our stockholders, which approval was obtained on September 8, 2023, the expiration or termination of the applicable waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, the receipt of the required state regulatory approvals, the absence of any law or order that has the effect of enjoining or otherwise prohibiting the completion of the Merger, and the expiration or termination of the waiting period (and any extension thereof) applicable to the consummation of the transactions contemplated by the Merger Agreement under all applicable antitrust laws without the imposition by any governmental entity of any term, condition, obligation, requirement, limitation, prohibition, remedy, sanction or other action that has resulted in or would reasonably be expected to result in a Burdensome Condition (as defined in the Merger Agreement). We can provide no assurance that all required consents and approvals will be obtained or that all closing conditions will otherwise be satisfied (or waived, if applicable), and, even if all required consents and approvals can be obtained and all closing conditions are satisfied (or waived, if applicable), we can provide no assurance as to the terms, conditions and timing of such consents and approvals or the timing of the completion of the Merger. Many of the conditions to completion of the Merger are not within our control, and we cannot predict when or if these conditions will be satisfied (or waived, if applicable). Any adverse consequence of the pending Merger could be exacerbated by any delays in completion of the Merger or termination of the Merger Agreement.

Each party’s obligation to consummate the Merger is also subject to the accuracy of the representations and warranties of the other party (subject to certain exceptions) and performance by each party of its respective obligations under the Merger Agreement, including an agreement by us to use our reasonable best efforts to carry on our business in all material respects in the ordinary course, consistent with past practice, and to preserve our business organization and relationships with customers, suppliers, licensors, licensees and other third parties, and to comply with certain operating covenants. In addition, the Merger Agreement may be terminated under certain specified circumstances, including, but not limited to, (1) if our board of directors makes an Amedisys Recommendation Change (as defined in the Merger Agreement) or (2) by our board of directors in order for us to enter into a definitive agreement for an alternative transaction with a third party with respect to an unsolicited Amedisys Superior Proposal (as defined in the Merger Agreement). As a result, we cannot assure you that the Merger will be completed, even though our stockholders approved the Merger, or that, if completed, it will be exactly on the terms set forth in the Merger Agreement or within the expected time frame.

We may not complete the proposed Merger within the time frame we anticipate or at all, which could have an adverse effect on our business, financial results and/or operations.

The proposed Merger may not be completed within the expected timeframe, or at all, as a result of various factors and conditions, some of which may be beyond our control. If the Merger is not completed for any reason, our stockholders will not receive any payment for their shares of our common stock in connection with the Merger. Instead, we will remain a public company, our common stock will continue to be listed and traded on The Nasdaq Global Select Market and registered under the Exchange Act, and we will be required to continue to file periodic reports with the SEC. Moreover, our ongoing business may be materially adversely affected, and we would be subject to a number of risks, including the following:

•we may experience negative reactions from the financial markets, including negative impacts on our stock price, and it is uncertain when, if ever, the price of our shares would return to the prices at which our shares currently trade;

•we may experience negative publicity, which could have an adverse effect on our ongoing operations including, but not limited to, retaining and attracting employees, customers, partners, suppliers and others with whom we do business;

•we will still be required to pay certain significant costs relating to the Merger, such as legal, accounting, financial advisory, printing and other professional services fees, which may relate to activities that we would not have undertaken other than in connection with the Merger;

•we may be required to pay a termination fee to UnitedHealth Group of $125,000,000, as required under the Merger Agreement under certain circumstances;

•we may be required to reimburse UnitedHealth Group for the $106,000,000 termination fee payment that UnitedHealth Group, on our behalf, paid to Option Care Health Inc. ("OPCH") in connection with the termination of the OPCH Merger Agreement under certain circumstances;

•while the Merger Agreement is in effect, we are subject to restrictions on our business activities, including, among other things, restrictions on our ability to engage in certain kinds of material transactions that would reasonably be expected to materially delay or prevent the consummation of the transaction contemplated by the Merger Agreement, which could prevent us from pursuing strategic business opportunities, taking actions with respect to our business that we may consider advantageous and responding effectively and/or timely to competitive pressures and industry developments, and may, as a result, materially adversely affect our business, results of operations and financial condition;

•matters relating to the Merger require substantial commitments of time and resources by our management, which could result in the distraction of management from ongoing business operations and pursuing other opportunities that could have been beneficial to us; and

•we may commit significant time and resources to defending against litigation related to the Merger.

If the Merger is not consummated, the risks described above may materialize, and they may have a material adverse effect on our business operations, financial results and stock price, particularly to the extent that the current market price of our common stock reflects an assumption that the Merger will be completed.

We will be subject to various uncertainties while the Merger is pending that may cause disruption and may make it more difficult to maintain relationships with employees, customers and other third-party business partners.

Our efforts to complete the Merger could cause substantial disruptions in, and create uncertainty surrounding, our business, which may materially adversely affect our results of operations and our business. Uncertainty as to whether the Merger will be completed may affect our ability to recruit prospective employees or to retain and motivate existing employees. Employee retention may be particularly challenging while the Merger is pending because employees may experience uncertainty about their roles following the Merger. As mentioned above, a substantial amount of our management’s and employees’ attention is being directed toward the completion of the Merger and thus is being diverted from our day-to-day operations. Uncertainty as to our future could adversely affect our business and our relationship with customers and potential customers. For example, customers, suppliers and other third parties may defer decisions concerning working with us or seek to change existing business relationships with us. Changes to or termination of existing business relationships could adversely affect our revenue, earnings and financial condition, as well as the market price of our common stock. The adverse effects of the pendency of the Merger could be exacerbated by any delays in completion of the Merger or termination of the Merger Agreement.

In certain instances, the Merger Agreement requires us to pay a termination fee to UnitedHealth Group, which could affect the decisions of a third party considering making an alternative acquisition proposal.

Under the terms of the Merger Agreement, we may be required to pay UnitedHealth Group a termination fee of $125,000,000 under specified conditions, including in the event the Merger Agreement is terminated due to a recommendation change by our board of directors, the termination of the Merger Agreement by our board of directors in order for us to enter into a definitive agreement with a third party for an alternative transaction with respect to an unsolicited Amedisys Superior Proposal or under certain circumstances where a proposal for an alternative transaction has been made to us and, within 12 months following termination, we enter into a definitive agreement providing for an alternative transaction or consummate an alternative transaction. Further, under specified circumstances, we may be required to reimburse UnitedHealth Group for the $106,000,000 termination fee payment that UnitedHealth Group, on our behalf, paid to OPCH in connection with the termination of the OPCH Merger Agreement. These payments could affect the structure, pricing and terms proposed by a third party seeking to acquire or merge with us and could discourage a third party from making a competing acquisition proposal, including a proposal that would be more favorable to our stockholders than the Merger.

We have incurred, and will continue to incur, direct and indirect costs as a result of the Merger.

We have incurred, and will continue to incur, significant costs and expenses, including regulatory costs, fees for professional services and other transaction costs in connection with the Merger, for which we will have received little or no benefit if the Merger is not completed. There are a number of factors beyond our control that could affect the total amount or the timing of these costs and expenses. Many of these fees and costs will be payable by us even if the Merger is not completed and may relate to activities that we would not have undertaken other than to complete the Merger.

Litigation challenging the Merger Agreement may prevent the Merger from being consummated within the expected timeframe or at all.

Following the announcement of the Merger and the filing of the Definitive Proxy Statement, purported stockholders filed complaints and sent Amedisys demand letters alleging that the Definitive Proxy Statement omitted material information that rendered it misleading or incomplete in violation of federal securities laws and that the Amedisys Board breached their fiduciary duties. Certain of the complaints have sought, among other things, an injunction enjoining the consummation of the Merger unless and until certain additional information is disclosed to Amedisys stockholders, rescissory damages, an accounting to the plaintiff for all damages suffered as a result of Amedisys' and Amedisys' Board's alleged wrongdoing, costs of the action, including plaintiffs' attorneys' fees and experts' fees, and other relief the court may deem just and proper. Amedisys also received a demand from a purported stockholder in connection with the Definitive Proxy Statement seeking to inspect certain Amedisys corporate books and records under Section 220 of the Delaware General Corporation Law. See the Company's Current Report on Form 8-K dated September 1, 2023 for additional information. Amedisys believes that the allegations in the complaints, demand letters and Section 220 demand letters lack merit and that Amedisys' disclosures have at all times complied with the applicable laws.

Nevertheless, lawsuits may continue to be filed against us, our Board of Directors or other parties to the Merger Agreement, challenging the Merger or making other claims in connection therewith. Such lawsuits may be brought by our purported stockholders and may seek, among other things, to enjoin consummation of the Merger. One of the conditions to the consummation of the Merger is the absence of any order or law that has the effect of enjoining or otherwise prohibiting the consummation of the Merger. As such, if the plaintiffs in such lawsuits are successful in obtaining an injunction prohibiting the defendants from completing the Merger on the agreed upon terms, then such injunction may prevent the Merger from becoming effective, or from becoming effective within the expected timeframe.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following table provides the information with respect to purchases made by us of shares of our common stock during each of the months during the three-month period ended September 30, 2023:


Period	(a) Total Number of Shares (or Units) Purchased		(b) Average Price Paid per Share (or Unit)		(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) That May Yet Be Purchased Under the Plans or Programs
July 1, 2023 to July 31, 2023	10,026		$	91.02	—	$	100,000,000
August 1, 2023 to August 31, 2023	30		93.25		—	100,000,000
September 1, 2023 to September 30, 2023	126		77.02		—	100,000,000
	10,182	(1)	$	90.85	—	$	100,000,000

(1)Includes shares of common stock surrendered to us by certain employees to satisfy tax withholding and/or strike price obligations in connection with the vesting of non-vested stock previously awarded to such employees under our 2018 Omnibus Incentive Compensation Plan.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

The exhibits marked with the cross symbol (†) are filed and the exhibits marked with a double cross (††) are furnished with this Form 10-Q. Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K.

Exhibit
Number

Document Description

Report or Registration Statement

SEC File or
Registration
Number

Exhibit
or Other
Reference

3.1

Composite of Certificate of Incorporation of the Company inclusive of all amendments through June 14, 2007

The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007

0-24260

3.1

3.2

Composite of By-Laws of the Company inclusive of all amendments through December 14, 2022

The Company’s Current Report on Form 8-K filed on December 16, 2022

0-24260

3.1

†31.1

Certification of Richard Ashworth, President and Chief Executive Officer (principal executive officer), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

†31.2

Certification of Scott G. Ginn, Chief Operating Officer, Executive Vice President and Chief Financial Officer (principal financial officer), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

††32.1

Certification of Richard Ashworth, President and Chief Executive Officer (principal executive officer), pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

††32.2

Certification of Scott G. Ginn, Chief Operating Officer, Executive Vice President and Chief Financial Officer (principal financial officer), pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

†101.INS

Inline XBRL Instance - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

†101.SCH

Inline XBRL Taxonomy Extension Schema Document

†101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

†101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase

†101.LAB

Inline XBRL Taxonomy Extension Labels Linkbase Document

†101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



AMEDISYS, INC. (Registrant)

By:						/s/ Allyson D. Guidroz
						Allyson D. Guidroz,
						Principal Accounting Officer and
						Duly Authorized Officer

Date: October 25, 2023

Exhibit 31.1

CERTIFICATION

I, Richard Ashworth, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, of Amedisys, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 25, 2023



/S/ Richard Ashworth
Richard Ashworth
President and Chief Executive Officer (Principal Executive Officer)

Exhibit 31.2

CERTIFICATION

I, Scott G. Ginn, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, of Amedisys, Inc.;

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 25, 2023



/S/ Scott G. Ginn
Scott G. Ginn Chief Operating Officer, Executive Vice President and Chief Financial Officer
(Principal Financial Officer)

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Amedisys, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2023 (the “Report”), I, Richard Ashworth, Chief Executive Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in the Report.

Date: October 25, 2023



/S/ Richard Ashworth
Richard Ashworth President and Chief Executive Officer
(Principal Executive Officer)

Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Amedisys, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2023 (the “Report”), I, Scott G. Ginn, Chief Operating Officer, Executive Vice President and Chief Financial Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

Date: October 25, 2023



/S/ Scott G. Ginn
Scott G. Ginn Chief Operating Officer, Executive Vice President and Chief Financial Officer
(Principal Financial Officer)

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2023	Oct. 20, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	0-24260
Entity Registrant Name	AMEDISYS INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3131700
Entity Address, Street Name	3854 American Way
Entity Address, Suite	Suite A
Entity Address, City	Baton Rouge
Entity Address, State	LA
Entity Address, Postal Zip Code	70816
City Area Code	225
Local Phone Number	292-2031
Title of each class	Common Stock, par value $0.001 per share
Trading Symbol	AMED
Name of each exchange on which registered	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		32,633,347
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Central Index Key	0000896262
Current Fiscal Year End Date	--12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 78,112	$ 40,540
Restricted cash	15,904	13,593
Patient accounts receivable	319,580	296,785
Prepaid expenses	20,534	11,628
Other current assets	33,097	26,415
Total current assets	467,227	388,961
Property and equipment, net of accumulated depreciation of $93,909 and $101,364	39,631	16,026
Operating lease right of use assets	87,834	102,856
Goodwill	1,244,679	1,287,399
Intangible assets, net of accumulated amortization of $12,838 and $14,604	103,634	101,167
Other assets	84,412	79,836
Total assets	2,027,417	1,976,245
Current liabilities:
Accounts payable	34,555	43,735
Payroll and employee benefits	126,989	125,387
Accrued expenses	139,100	137,390
Termination fee paid by UnitedHealth Group	106,000	0
Current portion of long-term obligations	35,364	15,496
Current portion of operating lease liabilities	26,111	33,521
Total current liabilities	468,119	355,529
Long-term obligations, less current portion	366,853	419,420
Operating lease liabilities, less current portion	61,878	69,504
Deferred income tax liabilities	35,398	20,411
Other long-term obligations	1,651	4,808
Total liabilities	933,899	869,672
Commitments and Contingencies—Note 6
Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding	0	0
Common stock, $0.001 par value, 60,000,000 shares authorized; 38,065,853 and 37,891,186 shares issued; 32,633,599 and 32,511,465 shares outstanding	38	38
Additional paid-in capital	776,880	755,063
Treasury stock, at cost, 5,432,254 and 5,379,721 shares of common stock	(465,613)	(461,200)
Retained earnings	728,603	757,672
Total Amedisys, Inc. stockholders’ equity	1,039,908	1,051,573
Noncontrolling interests	53,610	55,000
Total equity	1,093,518	1,106,573
Total liabilities and equity	$ 2,027,417	$ 1,976,245

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Property and equipment, accumulated depreciation	$ 93,909	$ 101,364
Intangible assets, accumulated amortization	$ 12,838	$ 14,604
Preferred stock, par value (usd per share)	$ 0.001	$ 0.001
Preferred stock, authorized (shares)	5,000,000	5,000,000
Preferred stock, issued (shares)	0	0
Preferred stock, outstanding (shares)	0	0
Common stock, par value (usd per share)	$ 0.001	$ 0.001
Common stock, authorized (shares)	60,000,000	60,000,000
Common stock, issued (shares)	38,065,853	37,891,186
Common stock, outstanding (shares)	32,633,599	32,511,465
Treasury stock at cost (shares)	5,432,254	5,379,721

CONSOLIDATED INCOME STATEMENT - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net service revenue	$ 556,237	$ 557,988	$ 1,665,594	$ 1,661,135
Cost of service, inclusive of depreciation	311,628	322,227	924,093	943,258
General and administrative expenses:
Salaries and benefits	129,083	125,550	380,926	376,788
Non-cash compensation	6,612	3,495	18,968	15,990
Merger-related expenses	4,980	0	25,151	0
Depreciation and amortization	4,436	5,477	13,604	19,705
Investment impairment	0	3,009	0	3,009
Other	57,287	59,299	180,467	167,851
Total operating expenses	514,026	519,057	1,543,209	1,526,601
Operating income	42,211	38,931	122,385	134,534
Other income (expense):
Interest income	1,304	59	2,452	108
Interest expense	(8,021)	(4,963)	(23,040)	(16,447)
Equity in earnings (loss) from equity method investments	1,252	302	9,366	(442)
Merger termination fee	0	0	(106,000)	0
Miscellaneous, net	1,201	491	5,262	1,155
Total other expense, net	(4,264)	(4,111)	(111,960)	(15,626)
Income before income taxes	37,947	34,820	10,425	118,908
Income tax expense	(12,331)	(9,417)	(40,381)	(32,755)
Net income (loss)	25,616	25,403	(29,956)	86,153
Net loss attributable to noncontrolling interests	344	239	887	739
Net income (loss) attributable to Amedisys, Inc.	$ 25,960	$ 25,642	$ (29,069)	$ 86,892
Basic earnings per common share:
Net income (loss) attributable to Amedisys, Inc. common stockholders	$ 0.80	$ 0.79	$ (0.89)	$ 2.67
Weighted average shares outstanding, basic (shares)	32,624	32,482	32,587	32,519
Diluted earnings per common share:
Net income (loss) attributable to Amedisys, Inc. common stockholders	$ 0.79	$ 0.79	$ (0.89)	$ 2.66
Weighted average shares outstanding, diluted (shares)	32,831	32,616	32,587	32,680

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Retained Earnings	Noncontrolling Interests
Balance, Stockholders Equity at Dec. 31, 2021	$ 976,323	$ 38	$ 728,118	$ (435,868)	$ 639,063	$ 44,972
Balance (in shares) at Dec. 31, 2021		37,674,868
Issuance of stock - employee stock purchase plan	2,857		2,857
Issuance of stock - employee stock purchase plan (shares)		24,159
Issuance/(cancellation) of non-vested stock	0	$ 0	0
Issuance/(cancellation) of non-vested stock (shares)		141,726
Exercise of stock options	1,078		1,078
Exercise of stock options (in shares)		11,306
Non-cash compensation	15,990		15,990
Surrendered Shares	(7,949)			(7,949)
Shares repurchased	(17,351)			(17,351)
Noncontrolling interest contributions	11,000					11,000
Noncontrolling interest distributions	(1,425)					(1,425)
Sale of noncontrolling interest	2,934		2,871			63
Net income (loss)	86,153				86,892	(739)
Balance, Stockholders Equity at Sep. 30, 2022	1,069,610	$ 38	750,914	(461,168)	725,955	53,871
Balance (in shares) at Sep. 30, 2022		37,852,059
Balance, Stockholders Equity at Jun. 30, 2022	1,038,995	$ 38	743,276	(457,981)	700,313	53,349
Balance (in shares) at Jun. 30, 2022		37,780,242
Issuance of stock - employee stock purchase plan	966		966
Issuance of stock - employee stock purchase plan (shares)		10,814
Issuance/(cancellation) of non-vested stock	0		0
Issuance/(cancellation) of non-vested stock (shares)		57,420
Exercise of stock options	306		306
Exercise of stock options (in shares)		3,583
Non-cash compensation	3,495		3,495
Surrendered Shares	(3,187)			(3,187)
Noncontrolling interest contributions	1,148					1,148
Noncontrolling interest distributions	(450)					(450)
Sale of noncontrolling interest	2,934		2,871			63
Net income (loss)	25,403				25,642	(239)
Balance, Stockholders Equity at Sep. 30, 2022	1,069,610	$ 38	750,914	(461,168)	725,955	53,871
Balance (in shares) at Sep. 30, 2022		37,852,059
Balance, Stockholders Equity at Dec. 31, 2022	1,106,573	$ 38	755,063	(461,200)	757,672	55,000
Balance (in shares) at Dec. 31, 2022		37,891,186
Issuance of stock - employee stock purchase plan	2,602		2,602
Issuance of stock - employee stock purchase plan (shares)		37,408
Issuance/(cancellation) of non-vested stock	0		0
Issuance/(cancellation) of non-vested stock (shares)		135,563
Exercise of stock options	100		100
Exercise of stock options (in shares)		1,696
Non-cash compensation	19,624		19,624
Surrendered Shares	(4,413)			(4,413)
Purchase of noncontrolling interest	(630)		(509)			(121)
Noncontrolling interest contributions	1,232					1,232
Noncontrolling interest distributions	(1,614)					(1,614)
Net income (loss)	(29,956)				(29,069)	(887)
Balance, Stockholders Equity at Sep. 30, 2023	1,093,518	$ 38	776,880	(465,613)	728,603	53,610
Balance (in shares) at Sep. 30, 2023		38,065,853
Balance, Stockholders Equity at Jun. 30, 2023	1,060,757	$ 38	768,789	(464,688)	702,643	53,975
Balance (in shares) at Jun. 30, 2023		38,030,397
Issuance of stock - employee stock purchase plan	848		848
Issuance of stock - employee stock purchase plan (shares)		10,915
Issuance/(cancellation) of non-vested stock	0		0
Issuance/(cancellation) of non-vested stock (shares)		24,117
Exercise of stock options	25		25
Exercise of stock options (in shares)		424
Non-cash compensation	7,243		7,243
Surrendered Shares	(925)			(925)
Purchase of noncontrolling interest	0		(25)			25
Noncontrolling interest contributions	856					856
Noncontrolling interest distributions	(902)					(902)
Net income (loss)	25,616				25,960	(344)
Balance, Stockholders Equity at Sep. 30, 2023	$ 1,093,518	$ 38	$ 776,880	$ (465,613)	$ 728,603	$ 53,610
Balance (in shares) at Sep. 30, 2023		38,065,853

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash Flows from Operating Activities:
Net (loss) income	$ (29,956)	$ 86,153
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization (inclusive of depreciation included in cost of service)	17,956	19,705
Non-cash compensation	19,624	15,990
Amortization and impairment of operating lease right of use assets	25,427	34,782
Loss on disposal of property and equipment	346	507
Loss on personal care divestiture	2,186	0
Merger termination fee	106,000	0
Deferred income taxes	15,417	19,031
Equity in (earnings) loss from equity method investments	(9,366)	442
Amortization of deferred debt issuance costs	743	743
Return on equity method investments	4,309	3,798
Investment impairment	0	3,009
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable	(32,934)	(18,266)
Other current assets	(15,434)	(19,929)
Operating lease right of use assets	(2,803)	(2,323)
Other assets	273	283
Accounts payable	(8,839)	5,886
Accrued expenses	10,340	(26,790)
Other long-term obligations	(3,156)	243
Operating lease liabilities	(23,256)	(30,864)
Net cash provided by operating activities	76,877	92,400
Cash Flows from Investing Activities:
Proceeds from the sale of deferred compensation plan assets	25	89
Proceeds from the sale of property and equipment	100	66
Purchases of property and equipment	(3,728)	(4,338)
Investments in technology assets	(6,881)	(848)
Investment in equity method investee	0	(637)
Purchase of cost method investment	0	(15,000)
Return of investment	150	0
Proceeds from personal care divestiture	47,787	0
Acquisitions of businesses, net of cash acquired	(350)	(71,952)
Net cash provided by (used in) investing activities	37,103	(92,620)
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options	100	1,078
Proceeds from issuance of stock under employee stock purchase plan	2,602	2,857
Shares withheld to pay taxes on non-cash compensation	(4,413)	(7,949)
Noncontrolling interest contributions	1,232	2,100
Noncontrolling interest distributions	(1,614)	(1,425)
Proceeds from sale of noncontrolling interest	0	3,941
Proceeds from borrowings under revolving line of credit	23,000	484,000
Repayments of borrowings under revolving line of credit	(23,000)	(465,500)
Principal payments of long-term obligations	(67,113)	(10,126)
Purchase of company stock	0	(17,351)
Payment of accrued contingent consideration	(4,091)	(5,714)
Purchase of noncontrolling interest	(800)	0
Net cash used in financing activities	(74,097)	(14,089)
Net increase (decrease) in cash, cash equivalents and restricted cash	39,883	(14,309)
Cash, cash equivalents and restricted cash at beginning of period	54,133	45,769
Cash, cash equivalents and restricted cash at end of period	94,016	31,460
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	19,787	9,153
Cash Paid For Infinity ZPIC Interest	0	11,544
Cash paid for income taxes, net of refunds received	24,318	23,582
Cash paid for operating lease liabilities	26,059	33,187
Cash paid for finance lease liabilities	8,462	1,074
Supplemental Disclosures of Non-Cash Activity:
Right of use assets obtained in exchange for operating lease liabilities	25,261	36,980
Right of use assets obtained in exchange for finance lease liabilities	34,964	1,846
Reductions to right of use assets resulting from reductions to operating lease liabilities	15,135	3,387
Reductions to right of use assets resulting from reductions to finance lease liabilities	1,209	564
Accrued contingent consideration	0	19,195
Noncontrolling interest contribution	$ 0	$ 8,900

NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS	NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as “Amedisys,” “we,” “us,” or “our”), is a multi-state provider of home health, hospice and high acuity care services with approximately 73% of our consolidated net service revenue derived from Medicare for the three and nine-month periods ended September 30, 2023, and approximately 74% of our consolidated net service revenue derived from Medicare for the three and nine-month periods ended September 30, 2022. As of September 30, 2023, we owned and operated 346 Medicare-certified home health care centers, 165 Medicare-certified hospice care centers and 10 admitting high acuity care joint ventures in 37 states within the United States and the District of Columbia. We divested our personal care business on March 31, 2023. Amedisys and UnitedHealth Group Incorporated Merger On June 26, 2023, Amedisys, UnitedHealth Group Incorporated, a Delaware corporation ("UnitedHealth Group"), and Aurora Holdings Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"), entered into an Agreement and Plan of Merger, pursuant to which Merger Sub will merge with and into Amedisys with Amedisys continuing as the surviving corporation and becoming a wholly owned subsidiary of UnitedHealth Group. See Note 4 - Mergers, Acquisitions and Dispositions for additional information. Basis of Presentation In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors. This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission (“SEC”) on February 16, 2023 (the “Form 10-K”), which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. Recently Issued Accounting Pronouncements In August 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-05, Business Combinations (Topic 805): Joint Venture Formations, which requires that a joint venture initially measure all contributions received upon its formation at fair value. The guidance is effective for joint ventures with a formation date on or after January 1, 2025 on a prospective basis. Use of Estimates Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Reclassification Certain reclassifications have been made to prior periods' financial statements in order to conform to the current year presentation. These reclassifications had no effect on our previously reported net income. See Note 7 - Segment Information for additional information regarding these reclassifications. Principles of Consolidation These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that we either consolidate, account for under the equity method of accounting or account for under the cost method of accounting. See Note 3 - Investments for additional information.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

Net service revenue by payor class as a percentage of total net service revenue for each segment is as follows:


	For the Three-Month Periods Ended September 30,				For the Nine-Month Periods Ended September 30,
	2023		2022		2023		2022
Home Health:
Medicare	39	%	40	%	39	%	40	%
Non-Medicare - Episodic-based	7	%	7	%	8	%	8	%
Non-Medicare - Non-episodic based	17	%	13	%	15	%	13	%
Hospice:
Medicare	34	%	34	%	34	%	33	%
Non-Medicare	2	%	2	%	2	%	2	%
Personal Care	—	%	3	%	1	%	3	%
High Acuity Care	1	%	1	%	1	%	1	%
	100	%	100	%	100	%	100	%

Home Health Revenue Recognition

Medicare Revenue

Non-Medicare Revenue

Hospice Revenue Recognition

Hospice Medicare Revenue

The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.

Hospice Non-Medicare Revenue

Personal Care Revenue Recognition

Personal Care Revenue

High Acuity Care Revenue Recognition

High Acuity Care Revenue

health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.

Cash, Cash Equivalents and Restricted Cash

The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):


	As of September 30, 2023		As of December 31, 2022
Cash and cash equivalents	$	78.1	$	40.5
Restricted cash	15.9		13.6
Cash, cash equivalents and restricted cash	$	94.0	$	54.1

Patient Accounts Receivable

We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.

Medicare Home Health

Medicare Hospice

Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care

Business Combinations

Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):


			Fair Value at Reporting Date Using
Financial Instrument	Carrying Value as of September 30, 2023		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-term obligations	$	377.5	$	—	$	373.3	$	—

•Level 1 – Quoted prices in active markets for identical assets and liabilities.

•Level 3 – Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.

Weighted-Average Shares Outstanding


	For the Three- Month Periods Ended September 30,		For the Nine- Month Periods Ended September 30,
	2023	2022	2023	2022
Weighted average number of shares outstanding - basic	32,624	32,482	32,587	32,519
Effect of dilutive securities:
Stock options	10	38	—	50
Non-vested stock and stock units	197	96	—	111
Weighted average number of shares outstanding - diluted	32,831	32,616	32,587	32,680
Anti-dilutive securities	248	202	652	276

INVESTMENTS

9 Months Ended

Sep. 30, 2023

Equity Method Investments and Joint Ventures [Abstract]

INVESTMENTS

During the three-month period ended September 30, 2022, we recorded a $3.0 million impairment charge in connection with the wind down of operations of one of our high acuity care joint ventures.


	As of September 30, 2023		As of December 31, 2022
ASSETS
Current assets:
Cash and cash equivalents	$	8.6	$	15.6
Patient accounts receivable	7.0		6.1
Other current assets	0.1		0.6
Total current assets	15.7		22.3
Property and equipment	0.1		0.1
Operating lease right of use assets	0.1		0.1
Goodwill	8.5		8.5
Intangible assets	0.4		0.4
Other assets	0.1		0.2
Total assets	$	24.9	$	31.6
LIABILITIES
Current liabilities:
Accounts payable	$	0.4	$	0.1
Payroll and employee benefits	0.8		0.5
Accrued expenses	6.9		5.8
Operating lease liabilities	—		0.1
Current portion of long-term obligations	—		0.2
Total liabilities	$	8.1	$	6.7

MERGERS AND ACQUISITIONS

9 Months Ended

Sep. 30, 2023

Business Combinations [Abstract]

MERGERS, ACQUISITIONS AND DISPOSITIONS

Mergers

On June 26, 2023, Amedisys, UnitedHealth Group Incorporated, a Delaware corporation ("UnitedHealth Group"), and Aurora Holdings Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"), entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which Merger Sub will merge with and into Amedisys with Amedisys continuing as the surviving corporation and becoming a wholly owned subsidiary of UnitedHealth Group (the “Merger”).

Acquisitions

2023 Acquisitions

2022 Acquisitions

$15 million of goodwill recorded for this acquisition will be deductible for income tax purposes over approximately two to five years.


	Amount
ASSETS
Patient accounts receivable	$	7.3
Prepaid expenses	0.2
Other current assets	0.1
Property and equipment	1.9
Operating lease right of use assets	3.2
Intangible assets (licenses)	1.3
Deferred income tax asset	0.1
Other assets	0.1
Total assets acquired	$	14.2
LIABILITIES
Accounts payable	$	(0.8)
Payroll and employee benefits	(2.6)
Accrued expenses	(2.6)
Operating lease liabilities	(2.8)
Current portion of long-term obligations	(0.6)
Total liabilities assumed	(9.4)
Net identifiable assets acquired	$	4.8
Goodwill	61.7
Total consideration	$	66.5

Dispositions


	As of December 31, 2022
ASSETS
Current assets:
Patient accounts receivable	$	9.6
Prepaid expenses	0.1
Total current assets	9.7
Property and equipment	0.1
Operating lease right of use assets	2.5
Goodwill	43.1
Total assets	$	55.4
LIABILITIES
Current liabilities:
Accounts payable	$	0.4
Payroll and employee benefits	0.6
Accrued expenses	1.8
Current portion of operating lease liabilities	0.6
Total current liabilities	3.4
Operating lease liabilities, less current portion	1.9
Total liabilities	$	5.3

LONG-TERM OBLIGATIONS

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

LONG-TERM OBLIGATIONS

Long-term debt consists of the following for the periods indicated (amounts in millions):


	September 30, 2023		December 31, 2022
$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Term SOFR plus Applicable Rate (7.2% at September 30, 2023); due July 30, 2026	$	377.5	$	435.9
$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Term SOFR plus Applicable Rate; due July 30, 2026	—		—
Promissory notes	—		0.2
Finance leases	27.5		2.3
Principal amount of long-term obligations	405.0		438.4
Deferred debt issuance costs	(2.8)		(3.5)
	402.2		434.9
Current portion of long-term obligations	(35.3)		(15.5)
Long-term obligations, less current portion	$	366.9	$	419.4

Second Amendment to the Credit Agreement

Third Amendment to the Credit Agreement


Pricing Tier	Consolidated Leverage Ratio	Base Rate Loans	Term SOFR Loans and SOFR Daily Floating Rate Loans	Commitment Fee	Letter of Credit Fee
I	> 3.00 to 1.0	1.00%	2.00%	0.30%	1.75%
II	< 3.00 to 1.0 but > 2.00 to 1.0	0.75%	1.75%	0.25%	1.50%
III	< 2.00 to 1.0 but > 0.75 to 1.0	0.50%	1.50%	0.20%	1.25%
IV	< 0.75 to 1.0	0.25%	1.25%	0.15%	1.00%

Joinder Agreements

Finance Leases

Our outstanding finance leases totaling $27.5 million relate to leased equipment and fleet vehicles and bear interest rates ranging from 2.2% to 8.0%.

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Legal Proceedings - Ongoing We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows. Legal fees related to all legal matters are expensed as incurred. Third Party Audits - Ongoing From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (“RACs”), Zone Program Integrity Contractors (“ZPICs”), Uniform Program Integrity Contractors (“UPICs”), Program Safeguard Contractors (“PSCs”), Medicaid Integrity Contractors (“MICs”), Supplemental Medical Review Contractors (“SMRCs”) and the Office of the Inspector General (“OIG”), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations. In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January 1, 2008 through March 31, 2010 (the “Review Period”) to determine whether the underlying services met pertinent Medicare payment requirements. We acquired the hospice operations subject to this review on August 1, 2009; the Review Period covered time periods both before and after our ownership of these hospice operations. Based on the ZPIC’s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June 6, 2011, the Medicare Administrative Contractor (“MAC”) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We disputed these findings, and our Florence subsidiary filed appeals through the Original Medicare Standard Appeals Process, in which we sought to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January 18, 2016, we received a letter dated January 6, 2016 referencing the ALJ hearing decision for the overpayment issued on June 6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million, including interest, based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid. No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of September 30, 2023, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August 1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $2.8 million. This amount is recorded as an indemnity receivable within other assets in our condensed consolidated balance sheets. In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (“SafeGuard”), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covered time periods both before and after our ownership of the care centers, which were acquired on December 31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters were based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers was reduced to $26.0 million, and the alleged overpayment for the Clearwater Care Center was reduced to $3.3 million. The Company filed Level III Administrative Appeals, and the ALJ hearings regarding the Lakeland Request for Repayment and the Clearwater Request for Repayment were held in April 2022. The Company received the results of the ALJ hearings in June 2022. The ALJ decisions for both the Clearwater Care Center and the Lakeland Care Centers were partially favorable for the claims that were reviewed, but the extrapolations were upheld. As a result, we increased our total accrual related to these matters from $17.4 million to $25.2 million, excluding interest. The repayment for the Lakeland Care Centers totaling $34.3 million ($22.8 million extrapolated repayment plus $11.5 million accrued interest) was made during the three-month period ended September 30, 2022. The repayment for the Clearwater Care Center totaling $3.7 million ($2.4 million extrapolated repayment plus $1.2 million accrued interest) was made during the three-month period ended December 31, 2022. Additionally, during the three-month period ended September 30, 2022, we wrote off $1.5 million of receivables that were impacted by these matters. We expect to be indemnified by the prior owners, upon exhaustion of the parties' appeal rights, for approximately $10.9 million and have recorded this amount within other assets in our condensed consolidated balance sheets as of September 30, 2023 and December 31, 2022. Insurance We are obligated for certain costs associated with our insurance programs, including employee health, workers’ compensation, professional liability and fleet. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis. Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers’ compensation insurance has a retention limit of $2.0 million per incident. Our professional liability insurance has a retention limit of $0.3 million per incident. Our fleet insurance has an exposure limit of $0.4 million per accident.

SEGMENT INFORMATION

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

SEGMENT INFORMATION


	For the Three-Month Period Ended September 30, 2023
	Home Health		Hospice		Personal Care		High Acuity Care		Other		Total
Net service revenue	$	351.6	$	200.2	$	—	$	4.4	$	—	$	556.2
Cost of service, inclusive of depreciation	201.6		104.2		—		5.8		—		311.6
General and administrative expenses	91.4		48.4		—		5.3		52.9		198.0
Depreciation and amortization	1.8		0.8		—		0.7		1.1		4.4
Operating expenses	294.8		153.4		—		11.8		54.0		514.0
Operating income (loss)	$	56.8	$	46.8	$	—	$	(7.4)	$	(54.0)	$	42.2

	For the Three-Month Period Ended September 30, 2022
	Home Health		Hospice		Personal Care		High Acuity Care		Other		Total
Net service revenue	$	339.2	$	198.7	$	16.6	$	3.5	$	—	$	558.0
Cost of service	196.7		109.4		12.2		3.9		—		322.2
General and administrative expenses	89.1		49.1		2.4		5.2		42.6		188.4
Depreciation and amortization	0.9		0.5		—		0.8		3.3		5.5
Investment impairment	—		—		—		3.0		—		3.0
Operating expenses	286.7		159.0		14.6		12.9		45.9		519.1
Operating income (loss)	$	52.5	$	39.7	$	2.0	$	(9.4)	$	(45.9)	$	38.9

	For the Nine-Month Period Ended September 30, 2023
	Home Health		Hospice		Personal Care		High Acuity Care		Other		Total
Net service revenue	$	1,044.7	$	592.8	$	15.0	$	13.1	$	—	$	1,665.6
Cost of service, inclusive of depreciation	593.1		304.4		11.1		15.5		—		924.1
General and administrative expenses	270.5		144.1		2.3		15.0		173.6		605.5
Depreciation and amortization	4.3		2.2		—		2.3		4.8		13.6
Operating expenses	867.9		450.7		13.4		32.8		178.4		1,543.2
Operating income (loss)	$	176.8	$	142.1	$	1.6	$	(19.7)	$	(178.4)	$	122.4

	For the Nine-Month Period Ended September 30, 2022
	Home Health		Hospice		Personal Care		High Acuity Care		Other		Total
Net service revenue	$	1,016.8	$	590.2	$	45.5	$	8.6	$	—	$	1,661.1
Cost of service	576.6		323.2		34.5		9.0		—		943.3
General and administrative expenses	261.1		152.1		6.8		14.6		126.0		560.6
Depreciation and amortization	3.3		1.7		0.1		2.4		12.2		19.7
Investment impairment	—		—		—		3.0		—		3.0
Operating expenses	841.0		477.0		41.4		29.0		138.2		1,526.6
Operating income (loss)	$	175.8	$	113.2	$	4.1	$	(20.4)	$	(138.2)	$	134.5

SHARE REPURCHASE SHARE REPURCHASE	9 Months Ended
SHARE REPURCHASE SHARE REPURCHASE	Sep. 30, 2023
Equity [Abstract]
SHARE REPURCHASE	SHARE REPURCHASES On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we could repurchase up to $100 million of our outstanding common stock through December 31, 2022 (the "2022 Share Repurchase Program"). Under the terms of the 2022 Share Repurchase Program, we were allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases were determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. Pursuant to this program, we repurchased 150,000 shares of our common stock at a weighted average price of $115.64 per share and a total cost of approximately $17 million during the nine-month period ended September 30, 2022. The repurchased shares were classified as treasury shares. The 2022 Share Repurchase Program expired on December 31, 2022. On February 2, 2023, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100 million of our outstanding common stock through December 31, 2023 (the "2023 Share Repurchase Program"). Under the terms of the 2023 Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. Effective January 1, 2023, repurchases are subject to a 1% excise tax under the Inflation Reduction Act. We have not repurchased any shares under the 2023 Share Repurchase Program as of September 30, 2023, and the Merger Agreement limits our ability to repurchase shares of our common stock prior to the completion of the Merger, subject to certain exceptions.

RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS	9 Months Ended
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS	Sep. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS We have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. We incurred costs of approximately $3.0 million and $8.3 million during the three and nine-month periods ended September 30, 2023, respectively, and $2.4 million and $7.1 million during the three and nine-month periods ended September 30, 2022, respectively, in connection with our usage of Medalogix's analytics platforms. We have an investment in a home health benefit manager, which is accounted for under the cost method. We incurred costs of approximately $0.3 million and $0.4 million during the three and nine-month periods ended September 30, 2023, respectively, in connection with our usage of the home health benefit manager's services.

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 25,960	$ 25,642	$ (29,069)	$ 86,892

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Basis of Presentation

Recently Issued Accounting Pronouncements

Recently Issued Accounting PronouncementsIn August 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-05, Business Combinations (Topic 805): Joint Venture Formations, which requires that a joint venture initially measure all contributions received upon its formation at fair value. The guidance is effective for joint ventures with a formation date on or after January 1, 2025 on a prospective basis.

Use of Estimates

Reclassification

Principles of Consolidation

Revenue Recognition

Net service revenue by payor class as a percentage of total net service revenue for each segment is as follows:


	For the Three-Month Periods Ended September 30,				For the Nine-Month Periods Ended September 30,
	2023		2022		2023		2022
Home Health:
Medicare	39	%	40	%	39	%	40	%
Non-Medicare - Episodic-based	7	%	7	%	8	%	8	%
Non-Medicare - Non-episodic based	17	%	13	%	15	%	13	%
Hospice:
Medicare	34	%	34	%	34	%	33	%
Non-Medicare	2	%	2	%	2	%	2	%
Personal Care	—	%	3	%	1	%	3	%
High Acuity Care	1	%	1	%	1	%	1	%
	100	%	100	%	100	%	100	%

Home Health Revenue Recognition

Medicare Revenue

Non-Medicare Revenue

Hospice Revenue Recognition

Hospice Medicare Revenue

The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.

Hospice Non-Medicare Revenue

Personal Care Revenue Recognition

Personal Care Revenue

High Acuity Care Revenue Recognition

High Acuity Care Revenue

health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.

Cash, Cash Equivalents and Restricted Cash

The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):


	As of September 30, 2023		As of December 31, 2022
Cash and cash equivalents	$	78.1	$	40.5
Restricted cash	15.9		13.6
Cash, cash equivalents and restricted cash	$	94.0	$	54.1

Patient Accounts Receivable

We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.

Medicare Home Health

Medicare Hospice

Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care

Business Combinations

Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):


			Fair Value at Reporting Date Using
Financial Instrument	Carrying Value as of September 30, 2023		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-term obligations	$	377.5	$	—	$	373.3	$	—

•Level 1 – Quoted prices in active markets for identical assets and liabilities.

•Level 3 – Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.

Weighted-Average Shares Outstanding

Weighted-Average Shares OutstandingNet income (loss) per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Schedule of Net Service Revenue by Payor Class

Net service revenue by payor class as a percentage of total net service revenue for each segment is as follows:


	For the Three-Month Periods Ended September 30,				For the Nine-Month Periods Ended September 30,
	2023		2022		2023		2022
Home Health:
Medicare	39	%	40	%	39	%	40	%
Non-Medicare - Episodic-based	7	%	7	%	8	%	8	%
Non-Medicare - Non-episodic based	17	%	13	%	15	%	13	%
Hospice:
Medicare	34	%	34	%	34	%	33	%
Non-Medicare	2	%	2	%	2	%	2	%
Personal Care	—	%	3	%	1	%	3	%
High Acuity Care	1	%	1	%	1	%	1	%
	100	%	100	%	100	%	100	%

Schedule of Cash Cash Equivalents and Restricted Cash

The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):


	As of September 30, 2023		As of December 31, 2022
Cash and cash equivalents	$	78.1	$	40.5
Restricted cash	15.9		13.6
Cash, cash equivalents and restricted cash	$	94.0	$	54.1

Schedule of Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):


			Fair Value at Reporting Date Using
Financial Instrument	Carrying Value as of September 30, 2023		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-term obligations	$	377.5	$	—	$	373.3	$	—

Schedule of Weighted-Average Shares Outstanding

The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income (loss) attributable to Amedisys, Inc. common stockholders (amounts in thousands):


	For the Three- Month Periods Ended September 30,		For the Nine- Month Periods Ended September 30,
	2023	2022	2023	2022
Weighted average number of shares outstanding - basic	32,624	32,482	32,587	32,519
Effect of dilutive securities:
Stock options	10	38	—	50
Non-vested stock and stock units	197	96	—	111
Weighted average number of shares outstanding - diluted	32,831	32,616	32,587	32,680
Anti-dilutive securities	248	202	652	276

INVESTMENTS (Tables)

9 Months Ended

Sep. 30, 2023

Equity Method Investments and Joint Ventures [Abstract]

Schedule of Variable Interest Entities


	As of September 30, 2023		As of December 31, 2022
ASSETS
Current assets:
Cash and cash equivalents	$	8.6	$	15.6
Patient accounts receivable	7.0		6.1
Other current assets	0.1		0.6
Total current assets	15.7		22.3
Property and equipment	0.1		0.1
Operating lease right of use assets	0.1		0.1
Goodwill	8.5		8.5
Intangible assets	0.4		0.4
Other assets	0.1		0.2
Total assets	$	24.9	$	31.6
LIABILITIES
Current liabilities:
Accounts payable	$	0.4	$	0.1
Payroll and employee benefits	0.8		0.5
Accrued expenses	6.9		5.8
Operating lease liabilities	—		0.1
Current portion of long-term obligations	—		0.2
Total liabilities	$	8.1	$	6.7

ACQUISITIONS (Tables)

9 Months Ended

Sep. 30, 2023

Business Combinations [Abstract]

Schedule of Business Acquisitions, Evolution Health

The total consideration of $66.5 million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):


	Amount
ASSETS
Patient accounts receivable	$	7.3
Prepaid expenses	0.2
Other current assets	0.1
Property and equipment	1.9
Operating lease right of use assets	3.2
Intangible assets (licenses)	1.3
Deferred income tax asset	0.1
Other assets	0.1
Total assets acquired	$	14.2
LIABILITIES
Accounts payable	$	(0.8)
Payroll and employee benefits	(2.6)
Accrued expenses	(2.6)
Operating lease liabilities	(2.8)
Current portion of long-term obligations	(0.6)
Total liabilities assumed	(9.4)
Net identifiable assets acquired	$	4.8
Goodwill	61.7
Total consideration	$	66.5

DISPOSITIONS (Tables)

9 Months Ended

Sep. 30, 2023

Discontinued Operations and Disposal Groups [Abstract]

Disposal Groups, Including Discontinued Operations

The carrying amounts of the assets and liabilities associated with our personal care reporting unit included in our condensed consolidated balance sheet as of December 31, 2022 were as follows (amounts in millions):


	As of December 31, 2022
ASSETS
Current assets:
Patient accounts receivable	$	9.6
Prepaid expenses	0.1
Total current assets	9.7
Property and equipment	0.1
Operating lease right of use assets	2.5
Goodwill	43.1
Total assets	$	55.4
LIABILITIES
Current liabilities:
Accounts payable	$	0.4
Payroll and employee benefits	0.6
Accrued expenses	1.8
Current portion of operating lease liabilities	0.6
Total current liabilities	3.4
Operating lease liabilities, less current portion	1.9
Total liabilities	$	5.3

LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Schedule of Long-Term Debt

Long-term debt consists of the following for the periods indicated (amounts in millions):


	September 30, 2023		December 31, 2022
$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Term SOFR plus Applicable Rate (7.2% at September 30, 2023); due July 30, 2026	$	377.5	$	435.9
$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Term SOFR plus Applicable Rate; due July 30, 2026	—		—
Promissory notes	—		0.2
Finance leases	27.5		2.3
Principal amount of long-term obligations	405.0		438.4
Deferred debt issuance costs	(2.8)		(3.5)
	402.2		434.9
Current portion of long-term obligations	(35.3)		(15.5)
Long-term obligations, less current portion	$	366.9	$	419.4

Schedule of Commitment Fee Under Credit Facilities

We are also subject to a commitment fee and letter of credit fee under the terms of the Third Amended Credit Agreement, as presented in the table below.


Pricing Tier	Consolidated Leverage Ratio	Base Rate Loans	Term SOFR Loans and SOFR Daily Floating Rate Loans	Commitment Fee	Letter of Credit Fee
I	> 3.00 to 1.0	1.00%	2.00%	0.30%	1.75%
II	< 3.00 to 1.0 but > 2.00 to 1.0	0.75%	1.75%	0.25%	1.50%
III	< 2.00 to 1.0 but > 0.75 to 1.0	0.50%	1.50%	0.20%	1.25%
IV	< 0.75 to 1.0	0.25%	1.25%	0.15%	1.00%

SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Schedule of Operating Income of Reportable Segments

Segment assets are not reviewed by the company’s chief operating decision maker and therefore are not disclosed below (amounts in millions).


	For the Three-Month Period Ended September 30, 2023
	Home Health		Hospice		Personal Care		High Acuity Care		Other		Total
Net service revenue	$	351.6	$	200.2	$	—	$	4.4	$	—	$	556.2
Cost of service, inclusive of depreciation	201.6		104.2		—		5.8		—		311.6
General and administrative expenses	91.4		48.4		—		5.3		52.9		198.0
Depreciation and amortization	1.8		0.8		—		0.7		1.1		4.4
Operating expenses	294.8		153.4		—		11.8		54.0		514.0
Operating income (loss)	$	56.8	$	46.8	$	—	$	(7.4)	$	(54.0)	$	42.2

	For the Three-Month Period Ended September 30, 2022
	Home Health		Hospice		Personal Care		High Acuity Care		Other		Total
Net service revenue	$	339.2	$	198.7	$	16.6	$	3.5	$	—	$	558.0
Cost of service	196.7		109.4		12.2		3.9		—		322.2
General and administrative expenses	89.1		49.1		2.4		5.2		42.6		188.4
Depreciation and amortization	0.9		0.5		—		0.8		3.3		5.5
Investment impairment	—		—		—		3.0		—		3.0
Operating expenses	286.7		159.0		14.6		12.9		45.9		519.1
Operating income (loss)	$	52.5	$	39.7	$	2.0	$	(9.4)	$	(45.9)	$	38.9

	For the Nine-Month Period Ended September 30, 2023
	Home Health		Hospice		Personal Care		High Acuity Care		Other		Total
Net service revenue	$	1,044.7	$	592.8	$	15.0	$	13.1	$	—	$	1,665.6
Cost of service, inclusive of depreciation	593.1		304.4		11.1		15.5		—		924.1
General and administrative expenses	270.5		144.1		2.3		15.0		173.6		605.5
Depreciation and amortization	4.3		2.2		—		2.3		4.8		13.6
Operating expenses	867.9		450.7		13.4		32.8		178.4		1,543.2
Operating income (loss)	$	176.8	$	142.1	$	1.6	$	(19.7)	$	(178.4)	$	122.4

	For the Nine-Month Period Ended September 30, 2022
	Home Health		Hospice		Personal Care		High Acuity Care		Other		Total
Net service revenue	$	1,016.8	$	590.2	$	45.5	$	8.6	$	—	$	1,661.1
Cost of service	576.6		323.2		34.5		9.0		—		943.3
General and administrative expenses	261.1		152.1		6.8		14.6		126.0		560.6
Depreciation and amortization	3.3		1.7		0.1		2.4		12.2		19.7
Investment impairment	—		—		—		3.0		—		3.0
Operating expenses	841.0		477.0		41.4		29.0		138.2		1,526.6
Operating income (loss)	$	175.8	$	113.2	$	4.1	$	(20.4)	$	(138.2)	$	134.5

NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2023 care_center numberOfJointVentures state	Sep. 30, 2022	Sep. 30, 2023 care_center numberOfJointVentures state	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Number of states with facilities \| state	37		37
Home Health [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Number of owned and operated care centers	346		346
Hospice [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Number of owned and operated care centers	165		165
High Acuity Care
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Number of Joint Ventures \| numberOfJointVentures	10		10
Revenue from Contract with Customer [Member] \| Product Concentration Risk \| Medicare Revenue [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Percent of net services revenue	73.00%	74.00%	73.00%	74.00%

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022	Sep. 30, 2023 USD ($) visit	Sep. 30, 2022	Dec. 31, 2022 USD ($)
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net service revenue period of care payment rate (days)			30 days
Percentage of total reimbursement of outlier payment			10.00%
Historical collection rate from Medicare			99.00%
Hospice Medicare revenue rate accounted for routine care	97.00%	97.00%	97.00%	97.00%
Net service revenue episode payment rate			60 days
Home Health [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Historical collection rate from Medicare			99.00%
Percentage Managed Care Contract Volume Able To Receive Additional Payments			30.00%
Home Health [Member] \| Minimum [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Low utilization payment adjustment, maximum number of visits \| visit			2
Non-Medicare revenue term rates			95.00%
Home Health [Member] \| Maximum [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Low utilization payment adjustment, maximum number of visits \| visit			6
Non-Medicare revenue term rates			100.00%
Hospice [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Historical collection rate from Medicare			99.00%
High Acuity Care \| Minimum [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net service revenue episode payment rate			30 days
Acute Phase for High Acuity Care Services			5 days
High Acuity Care \| Maximum [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net service revenue episode payment rate			60 days
Acute Phase for High Acuity Care Services			7 days
Cap Year 2017 Through 2023
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Estimated amounts due back to Medicare \| $	$ 3.5		$ 3.5
Cap Year 2016 Through 2023
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Estimated amounts due back to Medicare \| $					$ 4.3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue by payor class as a percentage of total net service revenue	100.00%	100.00%	100.00%	100.00%
Home Health Medicare [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue by payor class as a percentage of total net service revenue	39.00%	40.00%	39.00%	40.00%
Home Health Non-Medicare - Episodic Based [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue by payor class as a percentage of total net service revenue	7.00%	7.00%	8.00%	8.00%
Home Health Non-Medicare - Non-Episodic Based [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue by payor class as a percentage of total net service revenue	17.00%	13.00%	15.00%	13.00%
Hospice Medicare [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue by payor class as a percentage of total net service revenue	34.00%	34.00%	34.00%	33.00%
Hospice Non-Medicare [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue by payor class as a percentage of total net service revenue	2.00%	2.00%	2.00%	2.00%
Personal Care [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue by payor class as a percentage of total net service revenue	0.00%	3.00%	1.00%	3.00%
High Acuity Care
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue by payor class as a percentage of total net service revenue	1.00%	1.00%	1.00%	1.00%

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Restricted Cash and Cash Equivalents Items [Line Items]
Cash and cash equivalents	$ 78,112	$ 40,540
Restricted cash	15,904	13,593
Cash, Cash Equivalents and Restricted Cash	94,016	54,133	$ 31,460	$ 45,769
Various acquisitions and divestiture [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash	$ 15,900	$ 13,600

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Concentration Risk [Line Items]
Accounts receivable derived from Medicare	65.00%	67.00%
Net service revenue period of care payment rate (days)	30 days
Percentage of patient receivables outstanding	10.00%
Historical collection rate from Medicare	99.00%
Payor Concentration Risk \| Accounts Receivable \| Single Payor
Concentration Risk [Line Items]
Concentration risk (percent)	14.00%

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)	Sep. 30, 2023 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument Carrying Amount Excluding Finance Leases	$ 377,500,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Fair Value	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Fair Value	373,300,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Fair Value	$ 0

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Accounting Policies [Abstract]
Weighted average number of shares outstanding - basic (shares)	32,624	32,482	32,587	32,519
Effect of dilutive securities:
Stock options (shares)	10	38	0	50
Non-vested stock and stock units (shares)	197	96	0	111
Weighted average number of shares outstanding - diluted (shares)	32,831	32,616	32,587	32,680
Anti-dilutive securities (shares)	248	202	652	276

INVESTMENTS (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
INVESTMENTS (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Variable Interest Entity [Line Items]
Minimum ownership percentage for controlling interest (percent)	50.00%			50.00%
Maximum ownership percentage for equity method investment (percent)	50.00%			50.00%
Equity method investment, aggregate cost	$ 45,500			$ 45,500		$ 40,500
Maximum ownership percentage for cost method investment (percent)	20.00%			20.00%
Purchase of cost method investment			$ 15,000	$ 0	$ 15,000
Investment Owned, at Cost	$ 20,000			20,000		20,000
Investment impairment	0	$ 3,009		0	$ 3,009
Cash and cash equivalents	78,112			78,112		40,540
Patient accounts receivable	319,580			319,580		296,785
Other current assets	33,097			33,097		26,415
Total current assets	467,227			467,227		388,961
Property and equipment	39,631			39,631		16,026
Operating lease right of use assets	87,834			87,834		102,856
Goodwill	1,244,679			1,244,679		1,287,399
Intangible assets	103,634			103,634		101,167
Other assets	84,412			84,412		79,836
Total assets	2,027,417			2,027,417		1,976,245
Accounts payable	34,555			34,555		43,735
Payroll and employee benefits	126,989			126,989		125,387
Accrued expenses	139,100			139,100		137,390
Operating lease liabilities	26,111			26,111		33,521
Total liabilities	933,899			933,899		869,672
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Cash and cash equivalents	8,600			8,600		15,600
Patient accounts receivable	7,000			7,000		6,100
Other current assets	100			100		600
Total current assets	15,700			15,700		22,300
Property and equipment	100			100		100
Operating lease right of use assets	100			100		100
Goodwill	8,500			8,500		8,500
Intangible assets	400			400		400
Other assets	100			100		200
Total assets	24,900			24,900		31,600
Accounts payable	400			400		100
Payroll and employee benefits	800			800		500
Accrued expenses	6,900			6,900		5,800
Operating lease liabilities	0			0		100
Current portion of long-term obligations	0			0		200
Total liabilities	$ 8,100			$ 8,100		$ 6,700

MERGERS AND ACQUISITIONS - Narrative (Details)				3 Months Ended			9 Months Ended
MERGERS AND ACQUISITIONS - Narrative (Details)	Jun. 26, 2023 USD ($)	Jan. 20, 2023 USD ($)	Apr. 01, 2022 USD ($) care_center	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Business Acquisition [Line Items]
Termination fee paid by UnitedHealth Group							$ 106,000,000		$ 0
Restricted cash							15,904,000		$ 13,593,000
Accrued contingent consideration							0	$ 19,195,000
Option Care Health
Business Acquisition [Line Items]
Business Acquisition, Termination Fee				$ 106,000,000
UnitedHealth Group
Business Acquisition [Line Items]
Business Acquisition, Termination Fee							125,000,000
Home Health [Member] \| WEST VIRGINIA
Business Acquisition [Line Items]
Goodwill recorded during period							300,000
Total purchase price for acquisition		$ 400,000
Home Health [Member] \| Certificate of Need [Member] \| WEST VIRGINIA
Business Acquisition [Line Items]
Acquisition, other intangibles recorded		$ 100,000
Evolution Health \| Home Health [Member]
Business Acquisition [Line Items]
Payments to acquire business			$ 51,100,000
Acquisition, number of care centers acquired \| care_center			15
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables					$ 7,300,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense					200,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other					100,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment					1,900,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets					3,200,000
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets					100,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets					100,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets					14,200,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable					(800,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits					(2,600,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses					(2,600,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities					(2,800,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt					(600,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities					(9,400,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net					4,800,000
Goodwill recorded during period					61,700,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net					66,500,000	$ 66,500,000		$ 66,500,000
Business Acquisition Closing Payment Adjustment			$ 1,000,000			$ 1,300,000
Total purchase price for acquisition			67,800,000
Restricted cash			16,700,000				7,100,000
Accrued contingent consideration			15,700,000
Amount Released From Escrow							9,600,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount			$ 15,000,000
Goodwill, Other Increase					200,000
Decrease In Assets Acquired					200,000
Evolution Health \| Home Health [Member] \| Minimum [Member]
Business Acquisition [Line Items]
GoodwillDeductibleForIncomeTaxPurposesPeriod			2 years
Evolution Health \| Home Health [Member] \| Maximum [Member]
Business Acquisition [Line Items]
GoodwillDeductibleForIncomeTaxPurposesPeriod			5 years
Evolution Health \| Home Health [Member] \| License
Business Acquisition [Line Items]
Acquisition, other intangibles recorded					1,300,000
AssistedCare Home Health \| Home Health [Member]
Business Acquisition [Line Items]
Payments to acquire business			$ 22,200,000
Acquisition, number of care centers acquired \| care_center			2
Acquisition, other intangibles recorded			$ 700,000
Goodwill recorded during period					$ 24,000,000
GoodwillDeductibleForIncomeTaxPurposesPeriod			15 years
Total purchase price for acquisition			$ 24,700,000
Restricted cash			2,500,000				$ 2,500,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount			$ 24,000,000
AssistedCare Home Health \| Home Health [Member] \| Acquired Names [Member]
Business Acquisition [Line Items]
Weighted-average amortization period			1 year
Acquisition, other intangibles recorded			$ 100,000
AssistedCare Home Health \| Home Health [Member] \| Certificates Of Need
Business Acquisition [Line Items]
Acquisition, other intangibles recorded			200,000
AssistedCare Home Health \| Home Health [Member] \| License
Business Acquisition [Line Items]
Acquisition, other intangibles recorded			$ 500,000
UnitedHealth Group
Business Acquisition [Line Items]
Business Acquisition, Share Exchange Ratio	$ 101

Discontinued Operations and Disposal Groups (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Restricted cash	$ 15,904		$ 15,904		$ 13,593
Proceeds from personal care divestiture			47,787	$ 0
Loss on personal care divestiture			(2,186)	$ 0
Disposition, Closing Payment Adjustment		$ 1,000
Closing Payment Adjustment Paid By Buyer	100
Escrow Amount for Potential Losses			5,000
Goodwill, Period Decrease		43,100
Personal Care [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net					9,600
Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current					100
Disposal Group, Including Discontinued Operation, Assets, Current					9,700
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent					100
Disposal Group Including Discontinued Operation Operating Lease Right Of Use Assets Noncurrent					2,500
Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent					43,100
Disposal Group, Including Discontinued Operation, Total Assets					55,400
Disposal Group, Including Discontinued Operation, Accounts Payable, Current					400
Disposal Group Including Discontinued Operation Payroll and Employee Benefits Current					600
Disposal Group Including Discontinued Operation Accrued Expenses Current					1,800
Disposal Group Including Discontinued Operation Operating Lease Liabilities Current					600
Disposal Group, Including Discontinued Operation, Liabilities, Current					3,400
Disposal Group Including Discontinued Operation Operating Lease Liabilities Noncurrent					1,900
Disposal Group, Including Discontinued Operation, Total Liabilities					$ 5,300
Restricted cash	$ 6,000		$ 6,000
Proceeds from personal care divestiture		47,800
Loss on personal care divestiture		$ 2,200

LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Principal amount	$ 405.0	$ 438.4
Deferred debt issuance costs	(2.8)	(3.5)
Long-term obligations, including current portion	402.2	434.9
Current portion of long-term obligations	(35.3)	(15.5)
Long-term obligations, less current portion	366.9	419.4
Term Loan [Member] \| Four Hundred Fifty Million Term Loan Facility
Debt Instrument [Line Items]
Principal amount	377.5	435.9
Revolving Credit Facility [Member] \| Five Hundred Fifty Million Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Principal amount	0.0	0.0
Promissory Notes [Member]
Debt Instrument [Line Items]
Principal amount	0.0	0.2
Finance leases [Member]
Debt Instrument [Line Items]
Principal amount	$ 27.5	$ 2.3

LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Principal amount	$ 405.0	$ 438.4
Term Loan [Member] \| Four Hundred Fifty Million Term Loan Facility
Debt Instrument [Line Items]
Debt instrument, face amount	$ 450.0
Maturity Date	Jul. 30, 2026
Principal amount	$ 377.5	435.9
Term Loan [Member] \| Four Hundred Fifty Million Term Loan Facility \| Term SOFR [Member]
Debt Instrument [Line Items]
Debt Instrument Interest Rate at Period End	7.20%
Revolving Credit Facility [Member] \| Five Hundred Fifty Million Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 550.0
Maturity Date	Jul. 30, 2026
Principal amount	$ 0.0	$ 0.0

LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)	9 Months Ended
	Sep. 30, 2023
Consolidated Leverage Ratio: Greater Than 3.00 to 1.0
Line of Credit Facility [Line Items]
Commitment fee percentage	0.30%
Letter Of Credit Fee	1.75%
Consolidated Leverage Ratio: Greater Than 3.00 to 1.0 \| Term SOFR [Member]
Line of Credit Facility [Line Items]
Basis spread on variable rate	2.00%
Consolidated Leverage Ratio: Greater Than 3.00 to 1.0 \| Base Rate [Member]
Line of Credit Facility [Line Items]
Basis spread on variable rate	1.00%
Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0
Line of Credit Facility [Line Items]
Commitment fee percentage	0.25%
Letter Of Credit Fee	1.50%
Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0 \| Term SOFR [Member]
Line of Credit Facility [Line Items]
Basis spread on variable rate	1.75%
Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0 \| Base Rate [Member]
Line of Credit Facility [Line Items]
Basis spread on variable rate	0.75%
Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0
Line of Credit Facility [Line Items]
Commitment fee percentage	0.20%
Letter Of Credit Fee	1.25%
Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0 \| Term SOFR [Member]
Line of Credit Facility [Line Items]
Basis spread on variable rate	1.50%
Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0 \| Base Rate [Member]
Line of Credit Facility [Line Items]
Basis spread on variable rate	0.50%
Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0
Line of Credit Facility [Line Items]
Commitment fee percentage	0.15%
Letter Of Credit Fee	1.00%
Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0 \| Term SOFR [Member]
Line of Credit Facility [Line Items]
Basis spread on variable rate	1.25%
Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0 \| Base Rate [Member]
Line of Credit Facility [Line Items]
Basis spread on variable rate	0.25%
Minimum [Member] \| Consolidated Leverage Ratio: Greater Than 3.00 to 1.0
Line of Credit Facility [Line Items]
Consolidated Leverage Ratio	3.00
Minimum [Member] \| Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0
Line of Credit Facility [Line Items]
Consolidated Leverage Ratio	2.00
Minimum [Member] \| Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0
Line of Credit Facility [Line Items]
Consolidated Leverage Ratio	0.75
Maximum [Member] \| Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0
Line of Credit Facility [Line Items]
Consolidated Leverage Ratio	3.00
Maximum [Member] \| Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0
Line of Credit Facility [Line Items]
Consolidated Leverage Ratio	2.00
Maximum [Member] \| Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0
Line of Credit Facility [Line Items]
Consolidated Leverage Ratio	0.75

LONG-TERM OBLIGATIONS - Narrative (Details) - USD ($) $ in Millions			3 Months Ended		9 Months Ended		26 Months Ended	34 Months Ended	60 Months Ended
	Mar. 10, 2023	Jan. 01, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Jul. 30, 2026	Jul. 30, 2026	Dec. 31, 2022	Jul. 30, 2021
Debt Instrument [Line Items]
Consolidated leverage ratio			2.5		2.5		2.5
Consolidated interest coverage ratio			5.5		5.5		5.5
Principal amount			$ 405.0		$ 405.0		$ 405.0			$ 438.4
Reclassification Of Operating Lease To Finance Lease		$ 15.0
Term Loan [Member] \| Four Hundred Fifty Million Term Loan Facility
Debt Instrument [Line Items]
Debt instrument, face amount			$ 450.0		$ 450.0		450.0
Weighted average interest rate (percent)			7.10%	3.80%	6.60%	2.60%
Maturity Date					Jul. 30, 2026
Principal amount			$ 377.5		$ 377.5		377.5			435.9
Revolving Credit Facility [Member] \| Five Hundred Fifty Million Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, face amount			550.0		$ 550.0		550.0
Weighted average interest rate (percent)				4.20%		3.20%
Maturity Date					Jul. 30, 2026
Remaining availability under revolving credit facility			517.4		$ 517.4		517.4
Principal amount			0.0		0.0		0.0			0.0
Line of Credit [Member] \| Five Hundred Fifty Million Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Outstanding letters of credit			32.6		32.6		$ 32.6
Third Amended Credit Agreement
Debt Instrument [Line Items]
Additional interest rate above Federal Fund rate	0.50%
Additional interest rate above Term SOFR	1.00%
Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent	95.00%
Percentage of adjusted EBITDA that guarantor subsidiaries represent	70.00%
SOFR Adjustment	0.10%
Third Amended Credit Agreement \| Four Hundred Fifty Million Term Loan Facility
Debt Instrument [Line Items]
Debt Instrument Periodic Payment Percentage							0.625%
Promissory Notes [Member]
Debt Instrument [Line Items]
Principal amount			0.0		0.0		$ 0.0			0.2
Finance leases [Member]
Debt Instrument [Line Items]
Principal amount			$ 27.5		$ 27.5		$ 27.5			$ 2.3
Second Amended Credit Agreement
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity											$ 1,000.0
Second Amended Credit Agreement \| Five Hundred Fifty Million Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, face amount											550.0
Second Amended Credit Agreement \| Four Hundred Fifty Million Term Loan Facility
Debt Instrument [Line Items]
Debt instrument, face amount											$ 450.0
Base Rate [Member] \| Third Amended Credit Agreement
Debt Instrument [Line Items]
Description of variable rate basis	Fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Term SOFR for an interest period of one month plus 1% per annum.
Base Rate [Member] \| Third Amended Credit Agreement
Debt Instrument [Line Items]
Basis spread on variable rate					0.75%
Term SOFR [Member] \| Third Amended Credit Agreement
Debt Instrument [Line Items]
Description of variable rate basis	Quoted rate per annum equal to the SOFR for an interest period of one or three months (as selected by us) plus the SOFR adjustment of 0.10%
Term SOFR [Member] \| Term Loan [Member] \| Four Hundred Fifty Million Term Loan Facility
Debt Instrument [Line Items]
Debt Instrument Interest Rate at Period End			7.20%		7.20%		7.20%
Term SOFR [Member] \| Third Amended Credit Agreement
Debt Instrument [Line Items]
Basis spread on variable rate					1.75%
Minimum [Member] \| Third Amended Credit Agreement
Debt Instrument [Line Items]
Proceeds Received From Loan Party Of Subsidiary	$ 5.0
Minimum [Member] \| Finance leases [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			2.20%		2.20%		2.20%
Maximum [Member] \| Finance leases [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			8.00%		8.00%		8.00%
Subsequent Event \| Third Amended Credit Agreement
Debt Instrument [Line Items]
Maturity Date									Jul. 30, 2026
Subsequent Event \| Third Amended Credit Agreement \| Four Hundred Fifty Million Term Loan Facility
Debt Instrument [Line Items]
Debt Instrument Periodic Payment Percentage								1.25%

COMMITMENTS AND CONTINGENCIES - Narrative (Details) $ in Millions			1 Months Ended	3 Months Ended		9 Months Ended	27 Months Ended
	Jan. 18, 2016 USD ($) claim	Jun. 06, 2011 beneficiary	Aug. 31, 2017 USD ($) claim	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Mar. 31, 2010 beneficiary	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jan. 10, 2019 USD ($)
Loss Contingencies [Line Items]
Health insurance retention limit						$ 1.3
Workers compensation insurance retention limit						2.0
Professional liability insurance retention limit						0.3
Fleet Insurance Exposure Limit						0.4
South Carolina \| Hospice [Member]
Loss Contingencies [Line Items]
Number of beneficiaries \| beneficiary							30
Indemnity receivable						2.8
Indemnification amount											$ 2.8
South Carolina \| Hospice [Member] \| Extrapolated [Member]
Loss Contingencies [Line Items]
Number of beneficiaries \| beneficiary		16
South Carolina \| Hospice [Member] \| Unfavorable [Member]
Loss Contingencies [Line Items]
Recovery amount of overpayment made to subsidiary	$ 3.7
Recovery amount of overpayment made to subsidiary including interest	$ 5.6
Number of claims submitted by subsidiary \| claim	9
Recovery amount of over payment made to subsidiary including interest withheld						5.7
Safeguard Zone Program Integrity Contractor \| Florida
Loss Contingencies [Line Items]
Loss contingency accrual								$ 25.2	$ 17.4
Indemnity receivable				$ 10.9		$ 10.9
Accounts Receivable, Allowance for Credit Loss, Writeoff					$ 1.5
Safeguard Zone Program Integrity Contractor \| Lakeland, Florida \| Home Health [Member]
Loss Contingencies [Line Items]
Recovery amount of overpayment made to subsidiary			$ 34.0							$ 26.0
Number of claims submitted by subsidiary \| claim			72
Actual claims payment			$ 0.2
Error rate (percent)			100.00%
Total Legal Settlement Payment					34.3
Legal Settlement Payment Less Interest					22.8
Litigation Settlement Interest					$ 11.5
Safeguard Zone Program Integrity Contractor \| Clearwater, Florida \| Home Health [Member]
Loss Contingencies [Line Items]
Recovery amount of overpayment made to subsidiary			$ 4.8							$ 3.3
Number of claims submitted by subsidiary \| claim			70
Actual claims payment			$ 0.2
Error rate (percent)			100.00%
Total Legal Settlement Payment				3.7
Legal Settlement Payment Less Interest				2.4
Litigation Settlement Interest				$ 1.2

SEGMENT INFORMATION - Narrative (Details)	9 Months Ended
SEGMENT INFORMATION - Narrative (Details)	Sep. 30, 2023 Segments
Segment Reporting [Abstract]
Number of reportable business segments	3

SEGMENT INFORMATION - Operating Income of Reportable Segments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Net service revenue	$ 556,237	$ 557,988	$ 1,665,594	$ 1,661,135
Cost of service, inclusive of depreciation	311,628	322,227	924,093	943,258
General and administrative expenses	198,000	188,400	605,500	560,600
Depreciation and amortization	4,436	5,477	13,604	19,705
Investment impairment	0	3,009	0	3,009
Operating expenses	514,026	519,057	1,543,209	1,526,601
Operating income (loss)	42,211	38,931	122,385	134,534
Home Health [Member]
Segment Reporting Information [Line Items]
Net service revenue	351,600	339,200	1,044,700	1,016,800
Cost of service, inclusive of depreciation	201,600	196,700	593,100	576,600
General and administrative expenses	91,400	89,100	270,500	261,100
Depreciation and amortization	1,800	900	4,300	3,300
Investment impairment		0		0
Operating expenses	294,800	286,700	867,900	841,000
Operating income (loss)	56,800	52,500	176,800	175,800
Hospice [Member]
Segment Reporting Information [Line Items]
Net service revenue	200,200	198,700	592,800	590,200
Cost of service, inclusive of depreciation	104,200	109,400	304,400	323,200
General and administrative expenses	48,400	49,100	144,100	152,100
Depreciation and amortization	800	500	2,200	1,700
Investment impairment		0		0
Operating expenses	153,400	159,000	450,700	477,000
Operating income (loss)	46,800	39,700	142,100	113,200
Personal Care [Member]
Segment Reporting Information [Line Items]
Net service revenue	0	16,600	15,000	45,500
Cost of service, inclusive of depreciation	0	12,200	11,100	34,500
General and administrative expenses	0	2,400	2,300	6,800
Depreciation and amortization	0	0	0	100
Investment impairment		0		0
Operating expenses	0	14,600	13,400	41,400
Operating income (loss)	0	2,000	1,600	4,100
High Acuity Care
Segment Reporting Information [Line Items]
Net service revenue	4,400	3,500	13,100	8,600
Cost of service, inclusive of depreciation	5,800	3,900	15,500	9,000
General and administrative expenses	5,300	5,200	15,000	14,600
Depreciation and amortization	700	800	2,300	2,400
Investment impairment		3,000		3,000
Operating expenses	11,800	12,900	32,800	29,000
Operating income (loss)	(7,400)	(9,400)	(19,700)	(20,400)
Other
Segment Reporting Information [Line Items]
Net service revenue	0	0	0	0
Cost of service, inclusive of depreciation	0	0	0	0
General and administrative expenses	52,900	42,600	173,600	126,000
Depreciation and amortization	1,100	3,300	4,800	12,200
Investment impairment		0		0
Operating expenses	54,000	45,900	178,400	138,200
Operating income (loss)	$ (54,000)	$ (45,900)	$ (178,400)	$ (138,200)

SHARE REPURCHASE Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended		11 Months Ended	17 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Feb. 02, 2023	Aug. 02, 2021
Share Repurchase [Line Items]
Purchase of company stock	$ 0	$ 17,351
2022 Share Repurchase Program
Share Repurchase [Line Items]
Stock Repurchase Program, Authorized Amount						$ 100,000
Stock Repurchase Program Expiration Date				Dec. 31, 2022
Shares repurchased (shares)		150,000
Purchase of company stock		$ 17,000
Treasury Stock Acquired, Average Cost Per Share		$ 115.64
2023 Share Repurchase Program
Share Repurchase [Line Items]
Stock Repurchase Program, Authorized Amount					$ 100,000
2023 Share Repurchase Program \| Subsequent Event
Share Repurchase [Line Items]
Stock Repurchase Program Expiration Date			Dec. 31, 2023

RELATED PARTY TRANSACTIONS Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Medalogix [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction	$ 3.0	$ 2.4	$ 8.3	$ 7.1
Home Health Benefit Manager [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction	$ 0.3		$ 0.4

Amedisys (NASDAQ:AMED)
Historical Stock Chart
From Apr 2024 to May 2024

Amedisys (NASDAQ:AMED)
Historical Stock Chart
From May 2023 to May 2024

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

AMED Amedisys Inc

Amedisys Inc News

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

AMED Amedisys Inc

Amedisys Inc News

Your Recent History

Company

Business

Popular

Get The App